Coloplast — Call Transcript 2026

Ladies and gentlemen, welcome to the Coloplast Interim Financial Statement for H1 2025/26 conference call. I'm Lorenzo, the Chorus Call operator. I would like to remind you that all participants will be listen-only mode, and the conference is being recorded. The presentation will be followed by a Q&A session. You can register for question at any time by pressing star and one on your telephone. For operator assistance, please press star and zero. The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Anders Lonning-Skovgaard, Executive Vice President and CFO. Please go ahead, sir. Our Q2 2025/2026 conference call. I'm Anders Lonning-Skovgaard, CFO of Coloplast. I'm very happy to introduce our new President and CEO, Gavin Wood, who joined the company on May 1st. Please turn to slide number three. Thank you, Anders, good morning, everyone. As Anders mentioned, I joined Coloplast on May 1st, this is my first opportunity to speak with many of you. Let me briefly introduce myself and share what excites me about joining Coloplast for this next chapter. I've spent more than two decades in global medtech, leading commercial organizations and multi-billion dollar businesses across different regions and therapeutic areas. Most recently, I served as company Group Chair of Johnson & Johnson MedTech EMEA, with an organization of more than 7,000 employees and ownership across surgery, orthopedics, and cardiovascular solutions. Prior to this, I was the worldwide president of Ethicon's wound closure and healing business, before that, the Executive Vice President of Global Commercial at Mölnlycke. I started my medtech career as a sales rep at Ethicon Endo-Surgery, followed by a series of traditional roles across sales and sales management. It was there that I first saw the impact a medical device can have when it's used by a physician on a patient or a customer. That experience is what really attracted me to the medtech industry and has motivated me to stay. A bit of context on me personally. I'm Canadian by birth, currently living in Switzerland and relocating to Denmark. My career has come across multiple geographies and is shaped by a global mindset and a strong appreciation for different cultures and ways of working. As I begin this new chapter, I want to put a few words to why Coloplast and why now. First, the deep sense of purpose. Coloplast was born because a nurse saw her sister suffering and refused to accept it, and an engineer committed to bringing her idea to life. It was about solving a human problem. Second, the people. The people behind the business. Every conversation I've had has confirmed that Coloplast is full of great talent, passion, and commitment, and I can feel that. As in any company, it's the quality of the people that ultimately determines what's possible. Third, the ambition. Coloplast wants to write its next chapter to become even more impactful towards users, customers, and communities, helping 4 million people long term, about 2 times as many as we serve today. Our 2030 strategy, Impact4, is designed to build that future by setting the standard of care at scale, anchored in deep customer centricity, and that resonates with me deeply. I'm a builder at heart, and I see something meaningful that we can achieve together. The company has a strong legacy built over many years, and as I approach this role with curiosity and genuine respect for that history, at this stage, for me, it's all about building a perspective, forming a clear view of where the future growth opportunities may lie, and where the organization may need to challenge itself as we look ahead. At its core, this is about continuing what Coloplast has done well for many years, converting investment, focus, and execution into strong and sustainable returns over time. The way I lead is grounded in a few simple beliefs. I believe value is created when ambition is translated into a number of clear priorities, when decisions are made as close to the customers as possible, and when teams are empowered with accountability for outcomes. That's how consistency and momentum are built over time, and ultimately, I believe focus drives results. This all starts with people. I place a strong emphasis on developing leaders and creating the environment where teams can perform at their best, because the culture, people, and strength of an organization ultimately determines what's possible and what we can deliver together. As I start my new role, I will be spending time close to the business, engaging across the organization and in our key markets, deepening my understanding of the Impact4, and focusing on strong commercial execution from day one. This is about seeing how Coloplast operates in practice, how decisions are made, and how our teams deliver for impact for our customers each and every day. My focus is simple, building best-in-class talent to drive performance and results. I'm looking forward to meeting many of you on the road in the coming months. Coloplast was built by listening closely to our users and our customers, and I'm excited to keep learning, listening, and building the next chapter of this company together with the people who make it possible. With that, I'll hand back to Anders, who will take us through the financial results for the quarter. Please turn to slide number four. Thank you. Thank you, Gavin, and once again, a warm welcome to Coloplast. On April 23rd, we revised our guidance for full year 2025/2026 and pre-announced our results for the first half of 2025/2026. We delivered a very strong second quarter, excluding Wound & Tissue Repair, with solid underlying performance across the majority of the group. Now, let's take a closer look at today's results. Please turn to slide number 5. In Ostomy Care, organic growth was 5% for the first six months, and growth in Danish kroner was 1%. In Q2, organic growth was 7%, with growth in Danish kroner of 3%. Following a soft start in Q1, we saw the anticipated pickup in momentum in Q2, and we expect this good momentum and continued market share gains to continue into the second half of the year. From a product perspective, our SenSura Mio portfolio continues to be the main growth driver, followed by the Brava supporting products. From a geographical perspective, growth in the quarter was broad-based across regions with solid contribution from Europe, led by the U.K. and Germany. I would also like to call out the U.S., which delivered double-digit growth and continues to deliver strong underlying momentum from Q1. Our U.S. business is in a great shape. In H1, both Vizient and Premier, the two largest GPOs in the U.S., renewed Coloplast's national group purchasing agreements for Ostomy Care, and we are seeing good uptake of our latest SenSura Mio launches, the black bags and the new two-piece offering, which has been well received in the market. Our main challenge in Ostomy Care remains China, which saw another quarter with subdued growth due to the continued weak consumer sentiment and competitive pressures from domestic players in the community channel. For the full year, we now expect sales in China to decline slightly year-over-year. Outside China, the rest of our emerging markets contributed nicely to growth. In Continence Care, organic growth was 7% for the first six months, and growth in Danish kroner was 3%. In Q2, organic growth was 8%, and growth in Danish kroner was 4%. Growth in the quarter was driven by the Luja catheter portfolio, which performed strongly across key European markets and the U.S. The male catheter continued to perform well, while the female catheter saw a strong uptake in the quarter driven by Europe. Luja is our most important innovation in Continence Care in a decade, and it's encouraging to see how Luja continues to pick up momentum, becoming an increasingly larger share of our growth contribution within intermittent catheters. It's a great example of how customer-centric innovation, backed by compelling clinical evidence, is setting a new standard of care in the market. Our Bowel Care business also continued its good momentum and made a strong contribution to growth in the quarter, driven by the Peristeen portfolio in Europe. Voice and Respiratory Care posted 8% organic growth for the first six months, with growth in Danish kroner of 5%. In Q2, organic growth was also 8%, and growth in Danish kroner was also 5%. Growth in laryngectomy in Q2 was high single-digit and driven by an increase in the number of patients served in existing and new markets, as well as increase in patient value, driven by the Provox Life portfolio. Growth in tracheostomy in Q2 was mid-single-digit, driven by continued solid underlying demand, partly offset by phasing in distributor markets. From a geographical perspective, all regions contributed to growth driven by Europe and the U.S. In Wound & Tissue Repair, organic growth was 1% for the first six months, and growth in Danish kroner was -7%, with 3 percentage points negative impact from the skincare divestment in December 2024. In Q2, organic growth was -2%, and growth in Danish kroner was -6%. Q2 revenue from Biologics amounted to DKK 283 million, with 0% organic growth and 0% operating profit margin, excluding the PPA amortization. As also mentioned on the extraordinary conference call three weeks ago, we continue to see a healthy inpatient business with growth that remains at a healthy double-digit level despite a slight easing of momentum in Q2. On the other hand, our outpatient business is challenged with significant sales decline in line with the rest of the market. In advanced wound dressings, sales declined 2% in Q2 and 3% in the first half of the year. China detracted from growth due to the product return initiated in Q3 last year, with a negative revenue impact of around DKK 25 million in the quarter, similar to the impact in Q1. Outside China, Europe had a soft quarter across markets. In Interventional Urology, organic growth was 8% for the first six months, and growth in Danish kroner was 3%. In Q2, organic growth was 8%, and reported growth in Danish kroner was 2%. Growth in Q2 was mainly driven by continued strong momentum in the U.S. Men's Health business, driven by the Titan penile implants. Followed by Europe. On February 18th, 2026, Coloplast completed the acquisition of all shares and voting rights of Uromedica, a commercial stage medical technology company specializing in the treatment of stress urinary incontinence, with a solution highly complementary to our existing Men's Health business. The integration of Uromedica is progressing well, and the acquisition has been well received by our existing Men's Health customers. Before turning to the H1 financials, let me make one final remark on organic growth. While performance in the Wound & Tissue Repair franchise remains below our expectations, this reflects a set of external headwinds that we are actively addressing. Importantly, more than 80% of our business continues to perform well with solid growth and market share gains. With this, let's look at our H1 financials. Please turn to slide six. Reported revenue for the first six months increased by DKK 171 million, or 1% compared to last year. Organic growth contributed DKK 789 million, or around 6% to reported revenue. Inorganic revenue, mostly related to the divestment of the skincare business in December 2024, reduced reported revenue by DKK 70 million, or around 50 basis points. Foreign exchange rates had a negative impact of DKK 548 million, or 4 percentage points on reported revenue, mainly related to the depreciation of the U.S. dollar, the British pound, and a basket of emerging markets currencies against the Danish kroner. Please turn to slide seven. Gross profit for the first six months amounted to DKK 9.5 billion, corresponding to a gross margin of 67% compared to 68% last year. The gross margin was negatively impacted by currencies of around 60 basis points, mostly related to the depreciation of the U.S. dollar, the British sterling, and a basket of emerging markets currencies against the Danish kroner, and the appreciation of the Hungarian forint against the Danish kroner. Ramp-up cost in Costa Rica and Portugal also impacted the gross margin negatively. The negative impact was partly offset by lower inflation on freight compared to last year. Operating expenses for the first six months amounted to DKK 5.8 billion at 2% increase from last year. The distribution to sales ratio for the first six months was 33%, on par with last year. The growth in distribution costs were flat year-over-year, reflecting one-off logistics costs in the U.S. last year and lower sales costs in China this year, partly offset by Kerecis one-off costs this year. The development in distribution costs were also positively impacted by the depreciation of the U.S. dollar against the Danish kroner. The admin to sales ratio for the first six months was 5% compared to 4% last year, and includes around DKK 15 million in one-off advisory costs incurred by Kerecis in Q1 in connection with the recent CMS regulatory changes in the U.S. outpatient setting. The R&D to sales ratio for the first six months was 4% of sales compared to 3% last year. The increase was driven by high activity levels in Chronic Care and Biologics. Overall, this resulted in an operating profit before special items of DKK 3.7 billion in the first six months, or a 3% decrease compared to last year. The EBIT margin before special items in the period was 26% compared with 27% last year, reflecting around 70 basis points negative impact from currencies and around 40 basis points negative impact from Kerecis. In constant currencies, EBIT grew 5% compared to last year. Coloplast incurred special items expenses of DKK 3.1 billion in the first half of the year, of which DKK 3 billion relates to the Kerecis impairment loss. Financial items in the first six months were a net expense of DKK 63 million compared to a net expense of DKK 385 million last year, driven mostly by interest expenses related to the financing of the Atos Medical acquisition, which were largely offset by gains on exchange rate adjustments, mostly related to the U.S. dollar, Hungarian forint, and the Costa Rican colon. The tax expense in the first 6 months was DKK 121 million compared to an ordinary tax expense of DKK 717 million last year. The tax rate was 22% on par with the ordinary tax rate last year. Net profit before special items in the first six months was DKK 2.8 billion, or a 6% increase from last year when adjusted for the non-recurring tax expenses last year. Adjusted diluted earnings per share before special items increased by 5%. Please turn to slide number eight. Operating cash flow for the first six months was an inflow of DKK 3.7 billion compared to an inflow of DKK 2.7 billion last year. The positive development in cash flows from operating activities was mostly driven by favorable development in working capital. Lower financial items also had a positive impact on cash flows, while higher income tax paid had a negative impact. Cash flow from investing activities was an outflow of DKK 1 billion compared to an outflow of DKK 442 million last year. CAPEX in the first six months was 6% of sales compared with 4% last year, and includes investments related to the new manufacturing site in Portugal, expected to be in operation in Q4 2025-2026. As a result, the free cash flow for the first six months was an inflow of DKK 2.7 billion compared to an inflow of DKK 2.3 billion last year, or a 16% increase. Excluding acquisition costs this year and benefits from the divestment last year, the free cash flow increased 33% in the first half 2025-2026, with a free cash flow to sales ratio of 20% compared to 15% last year. The trailing 12-month cash conversion was 89%, and net working capital amounted to around 25% of sales. Lastly, the board of directors approved a half-year interim dividend of DKK 5 per share, corresponding to a total interim dividend payout of approximately DKK 1.1 billion. Let's take a brief look at the financial guidance for the year. Please turn to slide number nine. As I mentioned earlier, we revised our guidance for full year 2025, 2026 on April 23rd. Per the revised guidance, we now expect full year organic revenue growth of 5%-6%, EBIT growth in constant currencies before special items of around 5%, and return on invested capital after tax before special items of around 15%. We continue to expect negative impact from currencies with around 2 to 3 percentage points negative impact on reported revenue growth and around 80 basis points negative impact on the reported EBIT margin. We are especially seeing negative impact from the Hungarian forint, which has appreciated 6% against the Danish kroner since the Hungarian election on April 12th. In terms of phasing, we expect both organic growth and EBIT growth in constant currencies in the second half of the year to be similar level to the first half of the year. We continue to expect net financial items of around minus DKK 500 million based on spot rates as of May 8th, down from around DKK 1 billion in 2024-2025. Thank you very much. Operator, we are now ready to take questions. We will now begin the question-and-answer session. The first question comes from the line of Julien Dormois from Jefferies. Please go ahead. Julien, we cannot hear you. Maybe your line is on mute. Sorry, guys. That should be better now. Apologies. Good morning. Good morning, Gavin, and welcome to the company, and thanks Anders for taking the call. Two questions from my side, please. The first one relates, will probably be for Gavin Wood and relates to your arrival as new CEO of the company. Maybe just to help investors, if you maybe had to name your top three strategic priorities for the first 12, 18 months at the firm, what would they be? Maybe also which parts of the Impact4 strategic plan do you think might need a revision, if any? The second question is more on the current trends in Wound & Tissue Repair, which obviously has been hurt in Q2. What have you seen as into the third quarter? Have you seen any difference in the performance for either Kerecis or for the rest of the business in especially in Europe? Thank you. Julien, thanks a lot for your two questions. Let me take the second question and then Gavin will come back on question number one. To your second question around the current trend on our Wound & Tissue Repair. As we have been talking about at length, we revised our full year guidance to the organic growth of 5%-6%. That was driven by the Biologics business in the U.S. as we delivered around 0% growth here in the second quarter. We are expecting to be at that level or slightly below 0% for the rest of the year. That is the main driver of the revised guidance that we did two to three weeks ago. We have also, as I just mentioned, seen some slowdown here in Europe on the dressing side, in particular in France, and to some extent also in Germany, driven by price reforms. That's how we see it and that's what we are looking into for the second half of this financial year. Gavin? Thank you, Julien, for the, for the kind welcome and my first question. Maybe let me start by sharing a little bit about some of the things that I will bring to Coloplast, then I'll answer your question about priorities and my perspective on Impact4. I think the first thing for all investors and analysts that are listening, you know, I've come from a lot of broad medtech experience, you know, leading large global multi-billion dollar medtech businesses. I've had the opportunity to see all the various priorities across medtech, and I've operated at scale across multiple franchises and geographies and organizations where, you know, we tend to focus on consistency, clarity, and accountability matters each and every day. This experience has helped shaped how I think about, you know, driving leadership at scale and how to keep priorities really clear with decision-making that's disciplined and execution that's predictable as organizations grow and become larger. I also, you know, also bring a background in wound care from my days at Mölnlycke across from the other areas that I've mentioned. The second area, Julien, is really around leadership and talent. I think in large organizations, outcomes ultimately depend on the leaders that you put in critical roles and the standards that you set for them, so I'm gonna be spending a lot of time here. I've spent many years building leadership teams and developing talent, which I'm incredibly passionate about, and creating environments where people are both, you know, empowered but also held accountable for clear expectations and results. I think it's ultimately about instilling an ownership mindset across your entire leadership organization. I think that the third thing is I'm bringing, you know, deep experience across both Europe and U.S. I've spent a lot of my career in, you know, both continents, North America and Europe, and having the opportunity to lead innovation in a lot of, you know, global execution roles. I think that this is something that I bring that also reinforces the speed of execution, being able to see multiple geographies and different ways of doing things, sustain commercial intensity and credibility, building credibility with clinicians over time, and working in different environments and environments that establish, you know, a very clear benchmark for urgency, focus and leadership, and that's something I'm going to be looking towards. The last thing I just wanna share on background, and then I'm gonna get into a few of your specific questions, is I think commercial experience that's grounded in the front line is something that's needed at this point. I started my career in sales, and I've stayed close to the field throughout. This matters to me because it always gives you a very direct understanding of how trust is built with customers, how adoption really happens with products and technology, and what makes execution work in practice. I genuinely enjoy spending time with the frontline teams and customers because that's where you really truly learn how an organization's working, and I'm gonna be doing a lot more of that. To answer your question directly on my approach then for priorities, I'm really on a listening tour. Right now, like, my focus is getting closer to the business, getting to know our teams, our people, our users, our customers, and then I'm gonna form my perspective on the value drivers that will enable us to deliver on our ambition. You can think of that as a listening tour. If I think of the direction of Impact4, you know, what you asked specifically, it's really more my role is to create the environment to unlock the potential for our teams to really excel and execute. If you look at Impact4, it's founded on four principles, you know, driving growth, you know, through innovative customer offerings. That's innovation. I mean, that resonates with me. You know, unlocking next-level efficiency gains and operational efficiency, that's super important to keep a company strong long term. Embracing technology, you know, through tech and AI is gonna be a key enabler for all medtech companies over the next five to ten years to transform. Finally, you know, cultivating a winning and sustainable company. This is really about driving culture and the talent engine. If there's one area that I'm probably gonna particularly lean into, not change, I'm gonna spend a lot of time on really understanding the culture and the talent and the high performance across Coloplast because I believe that organizations that win long term in medtech, they win because they have a winning culture and a talent engine built for the future. Thank you for the question. Thank you very much, and good luck. The next question comes from the line of Doyle Graham from UBS. Please go ahead. Morning. Thanks, guys. Thanks for taking my questions. Gavin, let me take a couple for you, which is, firstly, just on, it's sort of follow-up to Julien's question, but maybe a little bit more specific, which if you look at the Coloplast share price, it's obviously been a disappointing share price for the last two, three years. When you think about what creates most value to the things that you can do, what metrics specifically are you focused on, just holistically, regardless of whether it's Coloplast or just when you look at a business in your prior experience, is it organic growth? Is it return on invested capital? Is it margin, EPS? What do you think is the one metric that you're kind of most focused on that can kind of move the dial? Maybe secondly, you talked about being in sort of prospective gathering mode. How long would you anticipate that taking? Thank you. Thank you for the question. Just for context, I just wanna be very, you know, direct with everyone. I'm less than two weeks in role, and clearly I'm still forming opinions and it's gonna take me some time to learn. I think, you know, pragmatically, I'm gonna need, you know, 90 days to really do this listening tour and learn and start to form some opinions where I can come back and share thoughts. This is what I can share right now. I think, you know, Coloplast has this admirable, you know, company and a great legacy that is incredibly strong. This is what attracted me to the organization. I'm really looking forward to getting into the business and getting to know the company at a deeper level. I'm getting, you know, getting to know the people, the leadership teams, the users, the customers. Over, you know, this next 90 days, this is gonna help me form my perspective on the value drivers that will enable us to deliver on our ambition. I think, you know, to be fair to you, the one area that I always think you lean in on is people. It's talent. Like, if you're saying, "What's the one metric?" You have to get the teams right. That, to me, is going to be the unlock in the future for everything. If you get the right people in the right roles, you get them engaged and motivated, you get them believing in the strategy, you get them believing in a winning culture, anything is possible. Thank you for the question. I need to just follow up then, just because I think people would like maybe something more concrete on that, which it's not to sort of hold you to anything, but again, it seems pretty reasonable just to. When you come in and look at the business, any business, what do you think is the best signifier of value creation? It's gonna be hard to measure culture, but we can measure return on invested capital. We can measure organic growth. Obviously for the last years that have come past, there's been different focuses. It's just generally to get a sense of when you come in and when you assess the business to start with, which were the things financially that you thought were attractive and could be enhanced? For me, you know, if I give something more concrete, it would be focusing on value creation. If there's one area that I typically look at from a strong commercial background, it's commercial execution. Okay. Okay. That's all right. Thank you. The next question comes from the line of Aisyah Noor from Morgan Stanley. Please go ahead. Hi. Good morning, everyone, and thanks for taking my question, and good to virtually meet you as well, Gavin. My first question as well is also for Gavin. It relates to your approach to innovation and R&D. Coloplast as an organization has a lot of projects underway, like Luja and Intibia. As you look at the organization today, do you see the current level of R&D investment as adequate, or do you think there's scope to raise that to kind of take the portfolio to a more competitive level? Then I have a financial follow-up for Anders after. Thank you. Thank you for the question. You know, first, you know, I certainly don't want to keep repeating myself. I am less than two weeks in. What I can share is innovation's important. There's absolutely no question. You know, I'm very happy to be very open with you with the innovation that Coloplast has started to put out, and I'm also very deeply committed to innovation going forward. The reality is it's still early days for me to give you a full assessment. You know, what I see in this organization is an organization that's innovation driven. It's been embedded in the company's DNA for a long time, has a strong purpose and mission, and it's clear when you meet our people and when I've met with the R&D teams, what makes people proud working at Coloplast is the difference that they make with innovative products that has a meaningful impact on users. I think what's also clear is this has allowed Coloplast to maintain a number of number one global market leading positions in their products and innovation. Without those, we certainly wouldn't be where we are today. You know, I will finish saying that as a newcomer to the company, I'm excited to start to build my own perspective on what the future holds for Coloplast. I'm excited about where we can take innovation. To answer your question, I'm really excited about some of the attractive assets that we have, like Luja, like Intibia, like Biologics. I think that what we're gonna see is more innovation coming out in these lines in the years to come that's gonna keep Coloplast strong and keep Coloplast innovative. Thank you for the question. Thanks a lot. My follow-up for Anders is, I guess one on profitability and margins. Can you just provide for us your assumptions on the cost inflation for raw materials in the second half, and how much safety inventory you have before this inflation headwind starts to kick in? Thank you. Yeah, let me take that one. Thanks. We also got this question at our call three weeks ago. We are following the Middle East situation very closely. We, as you know, we have around 50% of our cost of goods sold, that's raw materials. In the first half of this year, the inflation levels, raw material prices were around flattish. We have not seen any impact yet, but I am expecting some impact into the towards the end of this year, so in Q4. Right now, I'm assuming around a 1% impact on our raw materials. That is, of course, under the assumption that the conflict will end soon. We are also seeing a little bit of impact right now on our logistics costs. On the energy side, we are hedged, and we are not expecting anything there. My assumption right now is around 1% increase coming into our Q4, based on the current knowledge about the Middle East. Got it. Thank you so much. The next question comes from the line of Anna Ratcliffe from Bank of America. Please go ahead. Hi. Good morning, and thank you for taking the questions. Gavin, congratulations on the new role. Appreciate your commentary that you're only two weeks in, but I wanted to ask, as you get under the hood, what are your first impressions of the business? What drew you most to the role, and how are you thinking about the different Strengths and opportunities, and then maybe for Anders, I wanted to ask to dig a little bit into Interventional Urology and that high single-digit growth for this year. How sustainable is that going forward? How much of that is driven by easy comps from the recall last year? Any update you could give us on the Intibia launch timing would be helpful. Thanks again for taking the questions. Thanks, Anna. Thank you for the warm welcome. You know, maybe let me start with your question on why Coloplast and what excites me and then what have I, you know, seen in the first week and a half. I'll reiterate what I shared earlier. I think the big thing is the purpose. Like, it really excited me. Coming from an organization like Johnson & Johnson, which has a strong credo, coming into an organization like Coloplast, where you see something similar with this purpose-led organization, where you're trying to develop solutions for users and patients that really need to find a technology, this was extremely motivating for me, especially when you're actually being able to combine innovation to improving patient outcomes. The second, and I'll say it again, it's really the people. I had a chance through the process to meet more than just the board. You know, people that work at Coloplast have a deep connection. There's something special about this company that it's not just about talent and passion. They're deeply committed. This is something that motivated me. When you can work with an organization where people have a strong purpose, they put a lot of emphasis on building strong teams, and they work together collaboratively, and where you feel there's a lot of talent that you can develop, I think that's something that you can make an organization a lot better long term. The last thing was really around the ambition. I think Coloplast is very sincere. We wanna write this next chapter. Part of that chapter is clear and in the Impact4, and part of that chapter is still to be written. I think as a new CEO, this is what makes me super motivated to be here, that you've got a balance of, you know, a great foundation of strength and opportunities to build for the future. I think, you know, maybe to answer, you know, your question about what I'm seeing, there's a lot of pride in this organization. That's something that I saw, you know, even from I mean, I've been walking the halls now for six, seven days. People are proud here. They really believe in the purpose of Coloplast, and that's a superpower to me. I also feel that there's an excitement from the organization on what they can build for the future through Impact4, especially around innovation. We talked a little bit about that. I think that there's going to be some great opportunities for us to innovate in the future. You know, finally, you know, people wanna be developed, and I think that that's in all organizations. I came from an organization that was deeply committed to developing talent. I'm excited to be here, and I see that there is an organization that wants to be developed. And that's exceptionally important in a medtech organization. Thank you for the question. All right. Thanks, Gavin. To your second question around Urology, as mentioned earlier, our Urology business is really off to a good start. We have been growing around 8% in the two first quarters of this year, it is actually better than we had anticipated. We are expecting to keep this momentum for the remaining part of this year. It's really driven by our Men's Health business in the U.S. We continue to see a double-digit growth within our Men's Health. That's one thing. The second thing is that here in Europe, we are now recovering back from the recall we had last year. That is also impacting our Urology business, in particular here in Europe. To your question around Intibia, that process is running. We are expecting to get approval later this year in order to launch the solution in the first six months of next financial year. It's following the plan we have laid out. That's the update on Urology. The next question comes from the line of Veronika Dubajova from Citi. Please go ahead. Good morning, thank you for taking my questions. I have two, please. First of all, Gavin, welcome, and look forward to interacting with you going forward. My first question is for you. I guess I gotta try to ask this a little bit differently, but I think Graham made a very important point. Looking at the Coloplast share price, it has been a very meaningful underperformer versus the rest of the sector. You know, normally in situations like that, when a CEO is arriving, it is with a mandate to fix a bunch of problems. I'm curious whether you feel that, you know, this is a mandate that has been afforded to you by the board or not, and whether this is something that you are actively thinking about. You know, obviously appreciate all the great things you've mentioned about Coloplast, clearly, you know, sometimes even great companies need help. Maybe if you can talk a little bit around how you're thinking about that, I think that would be super helpful for us to all understand. My second question is a follow-up on Aisyah's question around inflation, and Anders. I just want to make sure I understood your comments there. Are you assuming inflation picks up in the fourth quarter of the fiscal or the calendar year? And I guess 1% doesn't sound like a very big number, to be blunt. You know, if I go back to sort of the type of inflationary pressure that we saw back in 2022, 2023, it was running in the mid to high single digits. Just maybe help me contextualize that and why you think this is much less severe this time around. Maybe some sensitivity as we move to fiscal 2027, assuming the conflict is not resolved, might also be helpful. Thanks, guys. Thanks, Veronika. Let me take the second question, the inflation question first. What we are looking into, as I mentioned earlier, is that with the knowledge I have right now, we are looking at around 1% impact on our raw materials. That is going to impact us, as I said earlier, here in Q3, but in particular in our Q4 of this year. Depending on when the conflict is going to finish, there will be an impact into next year. When that is said, we are not at all looking into inflation levels at the levels we saw back in 2022 or 2023 with the knowledge I have today. So that is by far not the levels we are looking into currently. The inflation is driven by, as you know, the higher oil price. Yes, we have some raw materials that are also impacted to some extent by the oil price, in particular injection molding chemicals. We are at least so far not looking into inflation levels as we saw in 2022. Gavin? Yes. Veronika, thank you for your question. You know, maybe let me try to answer it slightly differently. I'm a big believer that focus drives results and ultimately, you know, moving forward, the best way to improve Coloplast long term is to execute our strategy. The Impact4 strategy, it's all about setting the standard of care and becoming even more impactful towards our users, customers, and communities. A strategy is that's anchored in deep customer centricity, and this is one that resonates with me deeply as I shared earlier. I will say that I'm a builder at heart, and I do see something meaningful that we can achieve together as a company going forward. That direction, you know, has been set, my focus now is really, you know, identifying on how we can unlock the potential and create an environment for value creation going forward. I think that the last thing that I would share is, you know, I need some time to form, you know, a clearer view. It's. I can sense also from the questions, you know, it's too early. I need time to form a clearer view of where the future growth opportunities may lie, then, you know, likely where we need to challenge ourself, you know, as we look ahead. Once I have that view, I'll be very open in sharing it. I appreciate that, Gavin. I guess the question for all of us is, you know, there is a strategy that doesn't seem to be yielding the results for a while now. I guess what, you know, all of us are trying to understand is to what extent are you ready to throw out the rule book and start from scratch? I'll put it bluntly, that's really, I think, what we're all trying to understand. I don't know if you can comment on that. No, I think it's too early for me to comment on it. I think I'm gonna stay the course and, you know, believe in the strategy that I have. Got it. Thanks so much. The next question comes from the line of Martin Brenoe from Nordea. Please go ahead. Thank you very much for taking my questions, Anders and Gavin, and a warm welcome to you, Gavin. Veronika was asking most of my also pretty blunt questions here. Maybe just understanding, Gavin, on the wound care business. Given your background that you have as an outsider, you know, looking at the Coloplast in inside the wound industry, I would like to hear your early assessment of Coloplast wound care business. What shape do you see it, and what level of investments are needed to bring it to a competitive state? Maybe also your view on skin substitutes category. How do you view that market, and how do you see Kerecis playing a part of Coloplast going forward? Great. Thank you for the questions. Yeah, it actually, you know, early days, but it's also exciting to be back in wound care. It is an area I know well, and, you know, for those of you that don't know my background, I spent, you know, four and a half years at Mölnlycke and led this business, so I do know it well. It's a complex area, as everyone knows. That's something I think that we're all familiar with. It is the largest market that Coloplast is present in from a market opportunity. There are many competitors, and I'm excited to, you know, to be on the Coloplast side now to be able to drive our innovation. I think what I see early days, and we're talking very early days, is I see some exciting developments that we can build on. Like, just take, you know, one example, the new Biatain Silicone Fit innovative technology. We won the award by Vizient in the U.S. That's an important recognition and an important milestone as we attempt to build a stronger position in the U.S. dressings business. I think longer term, you have to be strong in the U.S. market to win in advanced wound care. Then you asked a question a little bit around, you know, Kerecis and, you know, my perspective on, you know, skin substitutes. I think that this is a very interesting area, and what I like about Kerecis is that we are underpinned with strong clinical data. I think that the market right now, it's a U.S. market, and some of the changes in the outpatient setting are a little bit unprecedented at time. I think it's gonna take time for this segment to arrive to a new normal. When you look forward, I think the intervention, you know, by the CMS and the segment of the market was needed to remove some unhealthy incentives that have kind of driven prices and spending to, you know, really, you know, remarkably unsustainable levels. However, the inpatient setting is governed by a completely different set of dynamics with strong emphasis on clinical evidence and efficacy and lower, more sustainable price levels. That's where Kerecis has a unique advantage with its proprietary fish skin technology. Kerecis is the only product based on intact fish skin. It comes with benefits from a sourcing, production, and logistics perspective. More importantly, the technology is remarkable in healing severe, difficult-to-heal wounds. You know, these wounds are so severe that you're often at times looking at amputations as an alternative. The clinical efficacy of fish skin products is remarkable, and the clinical evidence really speaks for itself. As we look ahead, inpatient, you know, in the U.S. is becoming a larger share of our overall Biologics business. That's up from 70% today. This is where we feel really confident going forward, and winning the inpatient setting is going to be critical to winning the overall category. I'm still early into the role, I know as I've said a few times, and still learning about the business, but I'm already now encouraged by the clinical efficacy and evidence behind Kerecis. I also like this balance between, you know, wound care and Kerecis together. You know, that's what I would say at this point. I've got a lot of experience in both Europe and U.S., you know, this is what I intend to leverage as I start to get deeper into the business segments. Thank you. Thank you, Gavin. That's very clear. Thank you for the question. If I can just squeeze one follow-up question into Anders regarding the inflation on the costs and the plastic prices. Just wanted to be sure that I understand exactly how you forecast. I've spoken to distributors of plastic, and they're talking about massive price increases over the summer. It hasn't happened yet, but we're going to see it over the summer. Just want to be sure that when you talk about you haven't seen sort of the impact yet, whether that is the prices that you are getting now, or whether you have actually been in contact with distributors about the price increases that you expect in the coming months. Thank you. Yeah, Martin, we are starting to see some of our raw material providers are contacting us. That's also what I'm basing my assumption for, in particular in Q4. What I said earlier, so far this year, we have not seen any impact yet, we are expecting some impact towards the end of this year, is in particular on some of the raw materials like injection molding, chemicals, films. That's how we see it currently. Thank you. What's your opportunity to pass on the cost? For this year, we have built that into the guidance we revised a few weeks ago. It's not going to be that material. We are going to manage that within the guidance we have given. Thank you very much for taking my questions. The next question comes from the line of Jan Koch from Deutsche Bank. Please go ahead. Good morning. Thanks for taking my two questions. The first one is regarding Kerecis. To better understand the growth potential for the upcoming fiscal year, could you provide the projected share of the outpatient setting in your guidance by the end of this year? Secondly, it's more clarification on your European wound care business. You recently mentioned a reimbursement pressure in Germany due to announced price reforms. Are you referring to the broader healthcare reform aiming to reduce overall healthcare costs in Germany? What kind of, yeah, price reforms are you seeing in Germany? Thank you. Thanks for your questions. In terms of Kerecis, as we have been talking about at length, our inpatient business is around 70%-80% of the total Kerecis business. This year so far, we have been growing a solid double-digits, and we also are expecting that to continue. It's really in the outpatient setting where we have had a significant impact from the reimbursement changes in the U.S., and that is really impacting us. We expect that to continue in the coming quarters. We will be sitting around at a 0% growth for the year. You should see this year, 2025, 2026 as a reset. We have also talked quite a lot about that our focus is on inpatient. As we have mentioned a number of times, we have a strong product portfolio based on fish skin. We have good clinical documentation. We have actually just released some new clinical documentation. Therefore, we are expecting that our inpatient business will continue to outgrow the market and drive market share gains. In terms of your second question, about Germany, yes, that there is a general healthcare reform going on in Germany. We are, it's still in progress, so there are no, you can say, conclusions yet. We are just flagging that there might be an impact, in particular on our dressings business, probably more into the coming year with the knowledge we have. However, it's based on what is, the conclusions are going to be. Okay, great. Thank you. Just a quick follow-up on my first question. Given that the outpatient channel is declining so significantly this year, how important is that channel for next fiscal year? Yeah. It's of course going to be less important, and our focus will be on inpatient. That's also how we set ourself up in our sales force. Go ahead. Thank you. The next question comes from the line of Martin Parkhøi from SEB. Please go ahead. Yes, Martin Parkhøi from SEB. I only have one question left, and that's for Gavin, also welcome to Coloplast. You are of course joining a great company with actually growth rates which many companies would envy. I think that the one of the problems which have been in the last many years has been the ability to deliver on both short-term and long-term guidance. Maybe that has been a tad too high. Maybe you can share how have you been able to deliver on budgets in your former jobs, and what is your approach to making budgets and guidance? Are you more a conservative kind of guy or a bullish kind of guy? How should we see that? First, Martin, thank you very much for the warm welcome and appreciate, you know, just once again, thrilled to be joining Coloplast and look forward to engaging with you in the future. I think, you know, I can't comment on guidance. Number one, it's too soon for me to kind of share a perspective here. I think that when you look at, you know, the previous organizations I worked in, it would be a little bit unfair as well. What I can share is I am deeply focused on a couple of things that I think will kinda give you an indication of the type of leader I am. I'm deeply focused on people, developing talent. I'm deeply focused on, you know, execution and driving growth. I believe in, you know, being a builder, building something for the future and I also believe that leaders should think like owners. When you get a group of people around this that are empowered and held accountable, and they have a common goal, I believe that you achieve, you know, really meaningful things together. I'm gonna reserve holding back on, you know, anything more specific at this time because it's just too new in my tenure. Thank you. All right. Thanks, Martin. That was the last questions, so we will conclude the conference call. Thanks a lot, Gavin, and again, a warm welcome to Coloplast. We are looking forward to see you on the street. Just thanks a lot. Thank you.

Speaker 10: Ladies and gentlemen, welcome to the Coloplast Interim Financial Statement for H1 2025/26 conference call. I'm Lorenzo, the Chorus Call operator. I would like to remind you that all participants will be listen-only mode, and the conference is being recorded. The presentation will be followed by a Q&A session. You can register for question at any time by pressing star and one on your telephone. For operator assistance, please press star and zero. The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Anders Lonning-Skovgaard, Executive Vice President and CFO. Please go ahead, sir. Ladies and gentlemen, welcome to the Coloplast Interim Financial Statement for H1 2025/26 conference call. ladies and gentlemen welcome to the coloplast interim financial statement for h1 2025/26 conference call I'm Lorenzo, the Chorus Call operator. i'm lorenzo the chorus call operator I would like to remind you that all participants will be listen-only mode, and the conference is being recorded. i would like to remind you that all participants will be listen-only mode and the conference is being recorded The presentation will be followed by a Q&A session. the presentation will be followed by a q&a session You can register for question at any time by pressing star and one on your telephone. you can register for question at any time by pressing star and one on your telephone For operator assistance, please press star and zero. for operator assistance please press star and zero The conference must not be recorded for publication or broadcast. the conference must not be recorded for publication or broadcast At this time, it's my pleasure to hand over to Anders Lonning-Skovgaard, Executive Vice President and CFO. at this time it's my pleasure to hand over to anders lonning-skovgaard executive vice president and cfo Please go ahead, sir. please go ahead sir

Speaker 2: Our Q2 2025/2026 conference call. I'm Anders Lonning-Skovgaard, CFO of Coloplast. I'm very happy to introduce our new President and CEO, Gavin Wood, who joined the company on May 1st. Please turn to slide number three. Our Q2 2025/2026 conference call. our q2 2025/2026 conference call I'm Anders Lonning-Skovgaard, CFO of Coloplast. i'm anders lonning-skovgaard cfo of coloplast I'm very happy to introduce our new President and CEO, Gavin Wood, who joined the company on May 1st. i'm very happy to introduce our new president and ceo gavin wood who joined the company on may 1st Please turn to slide number three. please turn to slide number three

Speaker 4: Thank you, Anders, good morning, everyone. As Anders mentioned, I joined Coloplast on May 1st, this is my first opportunity to speak with many of you. Let me briefly introduce myself and share what excites me about joining Coloplast for this next chapter. I've spent more than two decades in global medtech, leading commercial organizations and multi-billion dollar businesses across different regions and therapeutic areas. Most recently, I served as company Group Chair of Johnson & Johnson MedTech EMEA, with an organization of more than 7,000 employees and ownership across surgery, orthopedics, and cardiovascular solutions. Prior to this, I was the worldwide president of Ethicon's wound closure and healing business, before that, the Executive Vice President of Global Commercial at Mölnlycke. Thank you, Anders, good morning, everyone. thank you anders good morning everyone As Anders mentioned, I joined Coloplast on May 1st, this is my first opportunity to speak with many of you. as anders mentioned i joined coloplast on may 1st this is my first opportunity to speak with many of you Let me briefly introduce myself and share what excites me about joining Coloplast for this next chapter. let me briefly introduce myself and share what excites me about joining coloplast for this next chapter I've spent more than two decades in global medtech, leading commercial organizations and multi-billion dollar businesses across different regions and therapeutic areas. i've spent more than two decades in global medtech leading commercial organizations and multi-billion dollar businesses across different regions and therapeutic areas Most recently, I served as company Group Chair of Johnson & Johnson MedTech EMEA, with an organization of more than 7,000 employees and ownership across surgery, orthopedics, and cardiovascular solutions. most recently i served as company group chair of johnson & johnson medtech emea with an organization of more than 7,000 employees and ownership across surgery orthopedics and cardiovascular solutions Prior to this, I was the worldwide president of Ethicon's wound closure and healing business, before that, the Executive Vice President of Global Commercial at Mölnlycke. prior to this i was the worldwide president of ethicon's wound closure and healing business before that the executive vice president of global commercial at mölnlycke I started my medtech career as a sales rep at Ethicon Endo-Surgery, followed by a series of traditional roles across sales and sales management. It was there that I first saw the impact a medical device can have when it's used by a physician on a patient or a customer. That experience is what really attracted me to the medtech industry and has motivated me to stay. A bit of context on me personally. I'm Canadian by birth, currently living in Switzerland and relocating to Denmark. My career has come across multiple geographies and is shaped by a global mindset and a strong appreciation for different cultures and ways of working. As I begin this new chapter, I want to put a few words to why Coloplast and why now. First, the deep sense of purpose. I started my medtech career as a sales rep at Ethicon Endo-Surgery, followed by a series of traditional roles across sales and sales management. i started my medtech career as a sales rep at ethicon endo-surgery followed by a series of traditional roles across sales and sales management It was there that I first saw the impact a medical device can have when it's used by a physician on a patient or a customer. it was there that i first saw the impact a medical device can have when it's used by a physician on a patient or a customer That experience is what really attracted me to the medtech industry and has motivated me to stay. that experience is what really attracted me to the medtech industry and has motivated me to stay A bit of context on me personally. a bit of context on me personally I'm Canadian by birth, currently living in Switzerland and relocating to Denmark. i'm canadian by birth currently living in switzerland and relocating to denmark My career has come across multiple geographies and is shaped by a global mindset and a strong appreciation for different cultures and ways of working. my career has come across multiple geographies and is shaped by a global mindset and a strong appreciation for different cultures and ways of working As I begin this new chapter, I want to put a few words to why Coloplast and why now. as i begin this new chapter i want to put a few words to why coloplast and why now First, the deep sense of purpose. first the deep sense of purpose Coloplast was born because a nurse saw her sister suffering and refused to accept it, and an engineer committed to bringing her idea to life. It was about solving a human problem. Second, the people. The people behind the business. Every conversation I've had has confirmed that Coloplast is full of great talent, passion, and commitment, and I can feel that. As in any company, it's the quality of the people that ultimately determines what's possible. Third, the ambition. Coloplast wants to write its next chapter to become even more impactful towards users, customers, and communities, helping 4 million people long term, about 2 times as many as we serve today. Our 2030 strategy, Impact4, is designed to build that future by setting the standard of care at scale, anchored in deep customer centricity, and that resonates with me deeply. Coloplast was born because a nurse saw her sister suffering and refused to accept it, and an engineer committed to bringing her idea to life. coloplast was born because a nurse saw her sister suffering and refused to accept it and an engineer committed to bringing her idea to life It was about solving a human problem. it was about solving a human problem Second, the people. second the people The people behind the business. the people behind the business Every conversation I've had has confirmed that Coloplast is full of great talent, passion, and commitment, and I can feel that. every conversation i've had has confirmed that coloplast is full of great talent passion and commitment and i can feel that As in any company, it's the quality of the people that ultimately determines what's possible. as in any company it's the quality of the people that ultimately determines what's possible Third, the ambition. third the ambition Coloplast wants to write its next chapter to become even more impactful towards users, customers, and communities, helping 4 million people long term, about 2 times as many as we serve today. coloplast wants to write its next chapter to become even more impactful towards users customers and communities helping 4 million people long term about 2 times as many as we serve today Our 2030 strategy, Impact4, is designed to build that future by setting the standard of care at scale, anchored in deep customer centricity, and that resonates with me deeply. our 2030 strategy impact4 is designed to build that future by setting the standard of care at scale anchored in deep customer centricity and that resonates with me deeply I'm a builder at heart, and I see something meaningful that we can achieve together. The company has a strong legacy built over many years, and as I approach this role with curiosity and genuine respect for that history, at this stage, for me, it's all about building a perspective, forming a clear view of where the future growth opportunities may lie, and where the organization may need to challenge itself as we look ahead. At its core, this is about continuing what Coloplast has done well for many years, converting investment, focus, and execution into strong and sustainable returns over time. The way I lead is grounded in a few simple beliefs. I believe value is created when ambition is translated into a number of clear priorities, when decisions are made as close to the customers as possible, and when teams are empowered with accountability for outcomes. I'm a builder at heart, and I see something meaningful that we can achieve together. i'm a builder at heart and i see something meaningful that we can achieve together The company has a strong legacy built over many years, and as I approach this role with curiosity and genuine respect for that history, at this stage, for me, it's all about building a perspective, forming a clear view of where the future growth opportunities may lie, and where the organization may need to challenge itself as we look ahead. the company has a strong legacy built over many years and as i approach this role with curiosity and genuine respect for that history at this stage for me it's all about building a perspective forming a clear view of where the future growth opportunities may lie and where the organization may need to challenge itself as we look ahead At its core, this is about continuing what Coloplast has done well for many years, converting investment, focus, and execution into strong and sustainable returns over time. at its core this is about continuing what coloplast has done well for many years converting investment focus and execution into strong and sustainable returns over time The way I lead is grounded in a few simple beliefs. the way i lead is grounded in a few simple beliefs I believe value is created when ambition is translated into a number of clear priorities, when decisions are made as close to the customers as possible, and when teams are empowered with accountability for outcomes. i believe value is created when ambition is translated into a number of clear priorities when decisions are made as close to the customers as possible and when teams are empowered with accountability for outcomes That's how consistency and momentum are built over time, and ultimately, I believe focus drives results. This all starts with people. I place a strong emphasis on developing leaders and creating the environment where teams can perform at their best, because the culture, people, and strength of an organization ultimately determines what's possible and what we can deliver together. As I start my new role, I will be spending time close to the business, engaging across the organization and in our key markets, deepening my understanding of the Impact4, and focusing on strong commercial execution from day one. This is about seeing how Coloplast operates in practice, how decisions are made, and how our teams deliver for impact for our customers each and every day. My focus is simple, building best-in-class talent to drive performance and results. That's how consistency and momentum are built over time, and ultimately, I believe focus drives results. that's how consistency and momentum are built over time and ultimately i believe focus drives results This all starts with people. this all starts with people I place a strong emphasis on developing leaders and creating the environment where teams can perform at their best, because the culture, people, and strength of an organization ultimately determines what's possible and what we can deliver together. i place a strong emphasis on developing leaders and creating the environment where teams can perform at their best because the culture people and strength of an organization ultimately determines what's possible and what we can deliver together As I start my new role, I will be spending time close to the business, engaging across the organization and in our key markets, deepening my understanding of the Impact4, and focusing on strong commercial execution from day one. as i start my new role i will be spending time close to the business engaging across the organization and in our key markets deepening my understanding of the impact4 and focusing on strong commercial execution from day one This is about seeing how Coloplast operates in practice, how decisions are made, and how our teams deliver for impact for our customers each and every day. this is about seeing how coloplast operates in practice how decisions are made and how our teams deliver for impact for our customers each and every day My focus is simple, building best-in-class talent to drive performance and results. my focus is simple building best-in-class talent to drive performance and results I'm looking forward to meeting many of you on the road in the coming months. Coloplast was built by listening closely to our users and our customers, and I'm excited to keep learning, listening, and building the next chapter of this company together with the people who make it possible. With that, I'll hand back to Anders, who will take us through the financial results for the quarter. Please turn to slide number four. I'm looking forward to meeting many of you on the road in the coming months. Coloplast was built by listening closely to our users and our customers, and I'm excited to keep learning, listening, and building the next chapter of this company together with the people who make it possible. i'm looking forward to meeting many of you on the road in the coming months. coloplast was built by listening closely to our users and our customers and i'm excited to keep learning listening and building the next chapter of this company together with the people who make it possible With that, I'll hand back to Anders, who will take us through the financial results for the quarter. with that i'll hand back to anders who will take us through the financial results for the quarter Please turn to slide number four. please turn to slide number four

Speaker 2: Thank you. Thank you, Gavin, and once again, a warm welcome to Coloplast. On April 23rd, we revised our guidance for full year 2025/2026 and pre-announced our results for the first half of 2025/2026. We delivered a very strong second quarter, excluding Wound & Tissue Repair, with solid underlying performance across the majority of the group. Now, let's take a closer look at today's results. Please turn to slide number 5. In Ostomy Care, organic growth was 5% for the first six months, and growth in Danish kroner was 1%. In Q2, organic growth was 7%, with growth in Danish kroner of 3%. Following a soft start in Q1, we saw the anticipated pickup in momentum in Q2, and we expect this good momentum and continued market share gains to continue into the second half of the year. Thank you. thank you Thank you, Gavin, and once again, a warm welcome to Coloplast. thank you gavin and once again a warm welcome to coloplast On April 23rd, we revised our guidance for full year 2025/2026 and pre-announced our results for the first half of 2025/2026. on april 23rd we revised our guidance for full year 2025/2026 and pre-announced our results for the first half of 2025/2026 We delivered a very strong second quarter, excluding Wound & Tissue Repair, with solid underlying performance across the majority of the group. we delivered a very strong second quarter excluding wound & tissue repair with solid underlying performance across the majority of the group Now, let's take a closer look at today's results. now let's take a closer look at today's results Please turn to slide number 5. please turn to slide number 5 In Ostomy Care, organic growth was 5% for the first six months, and growth in Danish kroner was 1%. in ostomy care organic growth was 5% for the first six months and growth in danish kroner was 1% In Q2, organic growth was 7%, with growth in Danish kroner of 3%. in q2 organic growth was 7% with growth in danish kroner of 3% Following a soft start in Q1, we saw the anticipated pickup in momentum in Q2, and we expect this good momentum and continued market share gains to continue into the second half of the year. following a soft start in q1 we saw the anticipated pickup in momentum in q2 and we expect this good momentum and continued market share gains to continue into the second half of the year From a product perspective, our SenSura Mio portfolio continues to be the main growth driver, followed by the Brava supporting products. From a geographical perspective, growth in the quarter was broad-based across regions with solid contribution from Europe, led by the U.K. and Germany. I would also like to call out the U.S., which delivered double-digit growth and continues to deliver strong underlying momentum from Q1. Our U.S. business is in a great shape. In H1, both Vizient and Premier, the two largest GPOs in the U.S., renewed Coloplast's national group purchasing agreements for Ostomy Care, and we are seeing good uptake of our latest SenSura Mio launches, the black bags and the new two-piece offering, which has been well received in the market. From a product perspective, our SenSura Mio portfolio continues to be the main growth driver, followed by the Brava supporting products. from a product perspective our sensura mio portfolio continues to be the main growth driver followed by the brava supporting products From a geographical perspective, growth in the quarter was broad-based across regions with solid contribution from Europe, led by the U.K. and Germany. from a geographical perspective growth in the quarter was broad-based across regions with solid contribution from europe led by the u.k and germany I would also like to call out the U.S., which delivered double-digit growth and continues to deliver strong underlying momentum from Q1. i would also like to call out the u.s which delivered double-digit growth and continues to deliver strong underlying momentum from q1 Our U.S. business is in a great shape. our u.s business is in a great shape In H1, both Vizient and Premier, the two largest GPOs in the U.S., renewed Coloplast's national group purchasing agreements for Ostomy Care, and we are seeing good uptake of our latest SenSura Mio launches, the black bags and the new two-piece offering, which has been well received in the market. in h1 both vizient and premier the two largest gpos in the u.s renewed coloplast's national group purchasing agreements for ostomy care and we are seeing good uptake of our latest sensura mio launches the black bags and the new two-piece offering which has been well received in the market Our main challenge in Ostomy Care remains China, which saw another quarter with subdued growth due to the continued weak consumer sentiment and competitive pressures from domestic players in the community channel. For the full year, we now expect sales in China to decline slightly year-over-year. Outside China, the rest of our emerging markets contributed nicely to growth. In Continence Care, organic growth was 7% for the first six months, and growth in Danish kroner was 3%. In Q2, organic growth was 8%, and growth in Danish kroner was 4%. Growth in the quarter was driven by the Luja catheter portfolio, which performed strongly across key European markets and the U.S. The male catheter continued to perform well, while the female catheter saw a strong uptake in the quarter driven by Europe. Our main challenge in Ostomy Care remains China, which saw another quarter with subdued growth due to the continued weak consumer sentiment and competitive pressures from domestic players in the community channel. our main challenge in ostomy care remains china which saw another quarter with subdued growth due to the continued weak consumer sentiment and competitive pressures from domestic players in the community channel For the full year, we now expect sales in China to decline slightly year-over-year. for the full year we now expect sales in china to decline slightly year-over-year Outside China, the rest of our emerging markets contributed nicely to growth. outside china the rest of our emerging markets contributed nicely to growth In Continence Care, organic growth was 7% for the first six months, and growth in Danish kroner was 3%. in continence care organic growth was 7% for the first six months and growth in danish kroner was 3% In Q2, organic growth was 8%, and growth in Danish kroner was 4%. in q2 organic growth was 8% and growth in danish kroner was 4% Growth in the quarter was driven by the Luja catheter portfolio, which performed strongly across key European markets and the U.S. growth in the quarter was driven by the luja catheter portfolio which performed strongly across key european markets and the u.s The male catheter continued to perform well, while the female catheter saw a strong uptake in the quarter driven by Europe. the male catheter continued to perform well while the female catheter saw a strong uptake in the quarter driven by europe Luja is our most important innovation in Continence Care in a decade, and it's encouraging to see how Luja continues to pick up momentum, becoming an increasingly larger share of our growth contribution within intermittent catheters. It's a great example of how customer-centric innovation, backed by compelling clinical evidence, is setting a new standard of care in the market. Our Bowel Care business also continued its good momentum and made a strong contribution to growth in the quarter, driven by the Peristeen portfolio in Europe. Voice and Respiratory Care posted 8% organic growth for the first six months, with growth in Danish kroner of 5%. In Q2, organic growth was also 8%, and growth in Danish kroner was also 5%. Luja is our most important innovation in Continence Care in a decade, and it's encouraging to see how Luja continues to pick up momentum, becoming an increasingly larger share of our growth contribution within intermittent catheters. luja is our most important innovation in continence care in a decade and it's encouraging to see how luja continues to pick up momentum becoming an increasingly larger share of our growth contribution within intermittent catheters It's a great example of how customer-centric innovation, backed by compelling clinical evidence, is setting a new standard of care in the market. it's a great example of how customer-centric innovation backed by compelling clinical evidence is setting a new standard of care in the market Our Bowel Care business also continued its good momentum and made a strong contribution to growth in the quarter, driven by the Peristeen portfolio in Europe. our bowel care business also continued its good momentum and made a strong contribution to growth in the quarter driven by the peristeen portfolio in europe Voice and Respiratory Care posted 8% organic growth for the first six months, with growth in Danish kroner of 5%. voice and respiratory care posted 8% organic growth for the first six months with growth in danish kroner of 5% In Q2, organic growth was also 8%, and growth in Danish kroner was also 5%. in q2 organic growth was also 8% and growth in danish kroner was also 5% Growth in laryngectomy in Q2 was high single-digit and driven by an increase in the number of patients served in existing and new markets, as well as increase in patient value, driven by the Provox Life portfolio. Growth in tracheostomy in Q2 was mid-single-digit, driven by continued solid underlying demand, partly offset by phasing in distributor markets. From a geographical perspective, all regions contributed to growth driven by Europe and the U.S. In Wound & Tissue Repair, organic growth was 1% for the first six months, and growth in Danish kroner was -7%, with 3 percentage points negative impact from the skincare divestment in December 2024. In Q2, organic growth was -2%, and growth in Danish kroner was -6%. Growth in laryngectomy in Q2 was high single-digit and driven by an increase in the number of patients served in existing and new markets, as well as increase in patient value, driven by the Provox Life portfolio. growth in laryngectomy in q2 was high single-digit and driven by an increase in the number of patients served in existing and new markets as well as increase in patient value driven by the provox life portfolio Growth in tracheostomy in Q2 was mid-single-digit, driven by continued solid underlying demand, partly offset by phasing in distributor markets. growth in tracheostomy in q2 was mid-single-digit driven by continued solid underlying demand partly offset by phasing in distributor markets From a geographical perspective, all regions contributed to growth driven by Europe and the U.S. from a geographical perspective all regions contributed to growth driven by europe and the u.s In Wound & Tissue Repair, organic growth was 1% for the first six months, and growth in Danish kroner was -7%, with 3 percentage points negative impact from the skincare divestment in December 2024. in wound & tissue repair organic growth was 1% for the first six months and growth in danish kroner was -7% with 3 percentage points negative impact from the skincare divestment in december 2024 In Q2, organic growth was -2%, and growth in Danish kroner was -6%. in q2 organic growth was -2% and growth in danish kroner was -6% Q2 revenue from Biologics amounted to DKK 283 million, with 0% organic growth and 0% operating profit margin, excluding the PPA amortization. As also mentioned on the extraordinary conference call three weeks ago, we continue to see a healthy inpatient business with growth that remains at a healthy double-digit level despite a slight easing of momentum in Q2. On the other hand, our outpatient business is challenged with significant sales decline in line with the rest of the market. In advanced wound dressings, sales declined 2% in Q2 and 3% in the first half of the year. China detracted from growth due to the product return initiated in Q3 last year, with a negative revenue impact of around DKK 25 million in the quarter, similar to the impact in Q1. Outside China, Europe had a soft quarter across markets. Q2 revenue from Biologics amounted to DKK 283 million, with 0% organic growth and 0% operating profit margin, excluding the PPA amortization. q2 revenue from biologics amounted to dkk 283 million with 0% organic growth and 0% operating profit margin excluding the ppa amortization As also mentioned on the extraordinary conference call three weeks ago, we continue to see a healthy inpatient business with growth that remains at a healthy double-digit level despite a slight easing of momentum in Q2. as also mentioned on the extraordinary conference call three weeks ago we continue to see a healthy inpatient business with growth that remains at a healthy double-digit level despite a slight easing of momentum in q2 On the other hand, our outpatient business is challenged with significant sales decline in line with the rest of the market. on the other hand our outpatient business is challenged with significant sales decline in line with the rest of the market In advanced wound dressings, sales declined 2% in Q2 and 3% in the first half of the year. in advanced wound dressings sales declined 2% in q2 and 3% in the first half of the year China detracted from growth due to the product return initiated in Q3 last year, with a negative revenue impact of around DKK 25 million in the quarter, similar to the impact in Q1. china detracted from growth due to the product return initiated in q3 last year with a negative revenue impact of around dkk 25 million in the quarter similar to the impact in q1 Outside China, Europe had a soft quarter across markets. outside china europe had a soft quarter across markets In Interventional Urology, organic growth was 8% for the first six months, and growth in Danish kroner was 3%. In Q2, organic growth was 8%, and reported growth in Danish kroner was 2%. Growth in Q2 was mainly driven by continued strong momentum in the U.S. Men's Health business, driven by the Titan penile implants. Followed by Europe. On February 18th, 2026, Coloplast completed the acquisition of all shares and voting rights of Uromedica, a commercial stage medical technology company specializing in the treatment of stress urinary incontinence, with a solution highly complementary to our existing Men's Health business. The integration of Uromedica is progressing well, and the acquisition has been well received by our existing Men's Health customers. Before turning to the H1 financials, let me make one final remark on organic growth. In Interventional Urology, organic growth was 8% for the first six months, and growth in Danish kroner was 3%. in interventional urology organic growth was 8% for the first six months and growth in danish kroner was 3% In Q2, organic growth was 8%, and reported growth in Danish kroner was 2%. in q2 organic growth was 8% and reported growth in danish kroner was 2% Growth in Q2 was mainly driven by continued strong momentum in the U.S. growth in q2 was mainly driven by continued strong momentum in the u.s Men's Health business, driven by the Titan penile implants. men's health business driven by the titan penile implants Followed by Europe. followed by europe On February 18th, 2026, Coloplast completed the acquisition of all shares and voting rights of Uromedica, a commercial stage medical technology company specializing in the treatment of stress urinary incontinence, with a solution highly complementary to our existing Men's Health business. on february 18th 2026 coloplast completed the acquisition of all shares and voting rights of uromedica a commercial stage medical technology company specializing in the treatment of stress urinary incontinence with a solution highly complementary to our existing men's health business The integration of Uromedica is progressing well, and the acquisition has been well received by our existing Men's Health customers. the integration of uromedica is progressing well and the acquisition has been well received by our existing men's health customers Before turning to the H1 financials, let me make one final remark on organic growth. before turning to the h1 financials let me make one final remark on organic growth While performance in the Wound & Tissue Repair franchise remains below our expectations, this reflects a set of external headwinds that we are actively addressing. Importantly, more than 80% of our business continues to perform well with solid growth and market share gains. With this, let's look at our H1 financials. Please turn to slide six. Reported revenue for the first six months increased by DKK 171 million, or 1% compared to last year. Organic growth contributed DKK 789 million, or around 6% to reported revenue. Inorganic revenue, mostly related to the divestment of the skincare business in December 2024, reduced reported revenue by DKK 70 million, or around 50 basis points. While performance in the Wound & Tissue Repair franchise remains below our expectations, this reflects a set of external headwinds that we are actively addressing. while performance in the wound & tissue repair franchise remains below our expectations this reflects a set of external headwinds that we are actively addressing Importantly, more than 80% of our business continues to perform well with solid growth and market share gains. importantly more than 80% of our business continues to perform well with solid growth and market share gains With this, let's look at our H1 financials. with this let's look at our h1 financials Please turn to slide six. please turn to slide six Reported revenue for the first six months increased by DKK 171 million, or 1% compared to last year. reported revenue for the first six months increased by dkk 171 million or 1% compared to last year Organic growth contributed DKK 789 million, or around 6% to reported revenue. organic growth contributed dkk 789 million or around 6% to reported revenue Inorganic revenue, mostly related to the divestment of the skincare business in December 2024, reduced reported revenue by DKK 70 million, or around 50 basis points. inorganic revenue mostly related to the divestment of the skincare business in december 2024 reduced reported revenue by dkk 70 million or around 50 basis points Foreign exchange rates had a negative impact of DKK 548 million, or 4 percentage points on reported revenue, mainly related to the depreciation of the U.S. dollar, the British pound, and a basket of emerging markets currencies against the Danish kroner. Please turn to slide seven. Gross profit for the first six months amounted to DKK 9.5 billion, corresponding to a gross margin of 67% compared to 68% last year. The gross margin was negatively impacted by currencies of around 60 basis points, mostly related to the depreciation of the U.S. dollar, the British sterling, and a basket of emerging markets currencies against the Danish kroner, and the appreciation of the Hungarian forint against the Danish kroner. Ramp-up cost in Costa Rica and Portugal also impacted the gross margin negatively. Foreign exchange rates had a negative impact of DKK 548 million, or 4 percentage points on reported revenue, mainly related to the depreciation of the U.S. dollar, the British pound, and a basket of emerging markets currencies against the Danish kroner. foreign exchange rates had a negative impact of dkk 548 million or 4 percentage points on reported revenue mainly related to the depreciation of the u.s dollar the british pound and a basket of emerging markets currencies against the danish kroner Please turn to slide seven. please turn to slide seven Gross profit for the first six months amounted to DKK 9.5 billion, corresponding to a gross margin of 67% compared to 68% last year. gross profit for the first six months amounted to dkk 9.5 billion corresponding to a gross margin of 67% compared to 68% last year The gross margin was negatively impacted by currencies of around 60 basis points, mostly related to the depreciation of the U.S. dollar, the British sterling, and a basket of emerging markets currencies against the Danish kroner, and the appreciation of the Hungarian forint against the Danish kroner. the gross margin was negatively impacted by currencies of around 60 basis points mostly related to the depreciation of the u.s dollar the british sterling and a basket of emerging markets currencies against the danish kroner and the appreciation of the hungarian forint against the danish kroner Ramp-up cost in Costa Rica and Portugal also impacted the gross margin negatively. ramp-up cost in costa rica and portugal also impacted the gross margin negatively The negative impact was partly offset by lower inflation on freight compared to last year. Operating expenses for the first six months amounted to DKK 5.8 billion at 2% increase from last year. The distribution to sales ratio for the first six months was 33%, on par with last year. The growth in distribution costs were flat year-over-year, reflecting one-off logistics costs in the U.S. last year and lower sales costs in China this year, partly offset by Kerecis one-off costs this year. The development in distribution costs were also positively impacted by the depreciation of the U.S. dollar against the Danish kroner. The negative impact was partly offset by lower inflation on freight compared to last year. the negative impact was partly offset by lower inflation on freight compared to last year Operating expenses for the first six months amounted to DKK 5.8 billion at 2% increase from last year. operating expenses for the first six months amounted to dkk 5.8 billion at 2% increase from last year The distribution to sales ratio for the first six months was 33%, on par with last year. the distribution to sales ratio for the first six months was 33% on par with last year The growth in distribution costs were flat year-over-year, reflecting one-off logistics costs in the U.S. last year and lower sales costs in China this year, partly offset by Kerecis one-off costs this year. the growth in distribution costs were flat year-over-year reflecting one-off logistics costs in the u.s last year and lower sales costs in china this year partly offset by kerecis one-off costs this year The development in distribution costs were also positively impacted by the depreciation of the U.S. dollar against the Danish kroner. the development in distribution costs were also positively impacted by the depreciation of the u.s dollar against the danish kroner The admin to sales ratio for the first six months was 5% compared to 4% last year, and includes around DKK 15 million in one-off advisory costs incurred by Kerecis in Q1 in connection with the recent CMS regulatory changes in the U.S. outpatient setting. The R&D to sales ratio for the first six months was 4% of sales compared to 3% last year. The increase was driven by high activity levels in Chronic Care and Biologics. Overall, this resulted in an operating profit before special items of DKK 3.7 billion in the first six months, or a 3% decrease compared to last year. The EBIT margin before special items in the period was 26% compared with 27% last year, reflecting around 70 basis points negative impact from currencies and around 40 basis points negative impact from Kerecis. The admin to sales ratio for the first six months was 5% compared to 4% last year, and includes around DKK 15 million in one-off advisory costs incurred by Kerecis in Q1 in connection with the recent CMS regulatory changes in the U.S. outpatient setting. the admin to sales ratio for the first six months was 5% compared to 4% last year and includes around dkk 15 million in one-off advisory costs incurred by kerecis in q1 in connection with the recent cms regulatory changes in the u.s outpatient setting The R&D to sales ratio for the first six months was 4% of sales compared to 3% last year. the r&d to sales ratio for the first six months was 4% of sales compared to 3% last year The increase was driven by high activity levels in Chronic Care and Biologics. the increase was driven by high activity levels in chronic care and biologics Overall, this resulted in an operating profit before special items of DKK 3.7 billion in the first six months, or a 3% decrease compared to last year. overall this resulted in an operating profit before special items of dkk 3.7 billion in the first six months or a 3% decrease compared to last year The EBIT margin before special items in the period was 26% compared with 27% last year, reflecting around 70 basis points negative impact from currencies and around 40 basis points negative impact from Kerecis. the ebit margin before special items in the period was 26% compared with 27% last year reflecting around 70 basis points negative impact from currencies and around 40 basis points negative impact from kerecis In constant currencies, EBIT grew 5% compared to last year. Coloplast incurred special items expenses of DKK 3.1 billion in the first half of the year, of which DKK 3 billion relates to the Kerecis impairment loss. Financial items in the first six months were a net expense of DKK 63 million compared to a net expense of DKK 385 million last year, driven mostly by interest expenses related to the financing of the Atos Medical acquisition, which were largely offset by gains on exchange rate adjustments, mostly related to the U.S. dollar, Hungarian forint, and the Costa Rican colon. The tax expense in the first 6 months was DKK 121 million compared to an ordinary tax expense of DKK 717 million last year. In constant currencies, EBIT grew 5% compared to last year. in constant currencies ebit grew 5% compared to last year Coloplast incurred special items expenses of DKK 3.1 billion in the first half of the year, of which DKK 3 billion relates to the Kerecis impairment loss. coloplast incurred special items expenses of dkk 3.1 billion in the first half of the year of which dkk 3 billion relates to the kerecis impairment loss Financial items in the first six months were a net expense of DKK 63 million compared to a net expense of DKK 385 million last year, driven mostly by interest expenses related to the financing of the Atos Medical acquisition, which were largely offset by gains on exchange rate adjustments, mostly related to the U.S. dollar, Hungarian forint, and the Costa Rican colon. financial items in the first six months were a net expense of dkk 63 million compared to a net expense of dkk 385 million last year driven mostly by interest expenses related to the financing of the atos medical acquisition which were largely offset by gains on exchange rate adjustments mostly related to the u.s dollar hungarian forint and the costa rican colon The tax expense in the first 6 months was DKK 121 million compared to an ordinary tax expense of DKK 717 million last year. the tax expense in the first 6 months was dkk 121 million compared to an ordinary tax expense of dkk 717 million last year The tax rate was 22% on par with the ordinary tax rate last year. Net profit before special items in the first six months was DKK 2.8 billion, or a 6% increase from last year when adjusted for the non-recurring tax expenses last year. Adjusted diluted earnings per share before special items increased by 5%. Please turn to slide number eight. Operating cash flow for the first six months was an inflow of DKK 3.7 billion compared to an inflow of DKK 2.7 billion last year. The positive development in cash flows from operating activities was mostly driven by favorable development in working capital. Lower financial items also had a positive impact on cash flows, while higher income tax paid had a negative impact. The tax rate was 22% on par with the ordinary tax rate last year. the tax rate was 22% on par with the ordinary tax rate last year Net profit before special items in the first six months was DKK 2.8 billion, or a 6% increase from last year when adjusted for the non-recurring tax expenses last year. net profit before special items in the first six months was dkk 2.8 billion or a 6% increase from last year when adjusted for the non-recurring tax expenses last year Adjusted diluted earnings per share before special items increased by 5%. adjusted diluted earnings per share before special items increased by 5% Please turn to slide number eight. please turn to slide number eight Operating cash flow for the first six months was an inflow of DKK 3.7 billion compared to an inflow of DKK 2.7 billion last year. operating cash flow for the first six months was an inflow of dkk 3.7 billion compared to an inflow of dkk 2.7 billion last year The positive development in cash flows from operating activities was mostly driven by favorable development in working capital. the positive development in cash flows from operating activities was mostly driven by favorable development in working capital Lower financial items also had a positive impact on cash flows, while higher income tax paid had a negative impact. lower financial items also had a positive impact on cash flows while higher income tax paid had a negative impact Cash flow from investing activities was an outflow of DKK 1 billion compared to an outflow of DKK 442 million last year. CAPEX in the first six months was 6% of sales compared with 4% last year, and includes investments related to the new manufacturing site in Portugal, expected to be in operation in Q4 2025-2026. As a result, the free cash flow for the first six months was an inflow of DKK 2.7 billion compared to an inflow of DKK 2.3 billion last year, or a 16% increase. Excluding acquisition costs this year and benefits from the divestment last year, the free cash flow increased 33% in the first half 2025-2026, with a free cash flow to sales ratio of 20% compared to 15% last year. Cash flow from investing activities was an outflow of DKK 1 billion compared to an outflow of DKK 442 million last year. CAPEX in the first six months was 6% of sales compared with 4% last year, and includes investments related to the new manufacturing site in Portugal, expected to be in operation in Q4 2025-2026. cash flow from investing activities was an outflow of dkk 1 billion compared to an outflow of dkk 442 million last year. capex in the first six months was 6% of sales compared with 4% last year and includes investments related to the new manufacturing site in portugal expected to be in operation in q4 2025-2026 As a result, the free cash flow for the first six months was an inflow of DKK 2.7 billion compared to an inflow of DKK 2.3 billion last year, or a 16% increase. as a result the free cash flow for the first six months was an inflow of dkk 2.7 billion compared to an inflow of dkk 2.3 billion last year or a 16% increase Excluding acquisition costs this year and benefits from the divestment last year, the free cash flow increased 33% in the first half 2025-2026, with a free cash flow to sales ratio of 20% compared to 15% last year. excluding acquisition costs this year and benefits from the divestment last year the free cash flow increased 33% in the first half 2025-2026 with a free cash flow to sales ratio of 20% compared to 15% last year The trailing 12-month cash conversion was 89%, and net working capital amounted to around 25% of sales. Lastly, the board of directors approved a half-year interim dividend of DKK 5 per share, corresponding to a total interim dividend payout of approximately DKK 1.1 billion. Let's take a brief look at the financial guidance for the year. Please turn to slide number nine. As I mentioned earlier, we revised our guidance for full year 2025, 2026 on April 23rd. Per the revised guidance, we now expect full year organic revenue growth of 5%-6%, EBIT growth in constant currencies before special items of around 5%, and return on invested capital after tax before special items of around 15%. The trailing 12-month cash conversion was 89%, and net working capital amounted to around 25% of sales. the trailing 12-month cash conversion was 89% and net working capital amounted to around 25% of sales Lastly, the board of directors approved a half-year interim dividend of DKK 5 per share, corresponding to a total interim dividend payout of approximately DKK 1.1 billion. lastly the board of directors approved a half-year interim dividend of dkk 5 per share corresponding to a total interim dividend payout of approximately dkk 1.1 billion Let's take a brief look at the financial guidance for the year. let's take a brief look at the financial guidance for the year Please turn to slide number nine. please turn to slide number nine As I mentioned earlier, we revised our guidance for full year 2025, 2026 on April 23rd. as i mentioned earlier we revised our guidance for full year 2025 2026 on april 23rd Per the revised guidance, we now expect full year organic revenue growth of 5%-6%, EBIT growth in constant currencies before special items of around 5%, and return on invested capital after tax before special items of around 15%. per the revised guidance we now expect full year organic revenue growth of 5%-6% ebit growth in constant currencies before special items of around 5% and return on invested capital after tax before special items of around 15% We continue to expect negative impact from currencies with around 2 to 3 percentage points negative impact on reported revenue growth and around 80 basis points negative impact on the reported EBIT margin. We are especially seeing negative impact from the Hungarian forint, which has appreciated 6% against the Danish kroner since the Hungarian election on April 12th. In terms of phasing, we expect both organic growth and EBIT growth in constant currencies in the second half of the year to be similar level to the first half of the year. We continue to expect net financial items of around minus DKK 500 million based on spot rates as of May 8th, down from around DKK 1 billion in 2024-2025. Thank you very much. Operator, we are now ready to take questions. We continue to expect negative impact from currencies with around 2 to 3 percentage points negative impact on reported revenue growth and around 80 basis points negative impact on the reported EBIT margin. we continue to expect negative impact from currencies with around 2 to 3 percentage points negative impact on reported revenue growth and around 80 basis points negative impact on the reported ebit margin We are especially seeing negative impact from the Hungarian forint, which has appreciated 6% against the Danish kroner since the Hungarian election on April 12th. we are especially seeing negative impact from the hungarian forint which has appreciated 6% against the danish kroner since the hungarian election on april 12th In terms of phasing, we expect both organic growth and EBIT growth in constant currencies in the second half of the year to be similar level to the first half of the year. in terms of phasing we expect both organic growth and ebit growth in constant currencies in the second half of the year to be similar level to the first half of the year We continue to expect net financial items of around minus DKK 500 million based on spot rates as of May 8th, down from around DKK 1 billion in 2024-2025. we continue to expect net financial items of around minus dkk 500 million based on spot rates as of may 8th down from around dkk 1 billion in 2024-2025 Thank you very much. thank you very much Operator, we are now ready to take questions. operator we are now ready to take questions

Speaker 10: We will now begin the question-and-answer session. The first question comes from the line of Julien Dormois from Jefferies. Please go ahead. Julien, we cannot hear you. Maybe your line is on mute. We will now begin the question-and-answer session. we will now begin the question-and-answer session The first question comes from the line of Julien Dormois from Jefferies. the first question comes from the line of julien dormois from jefferies Please go ahead. please go ahead Julien, we cannot hear you. julien we cannot hear you Maybe your line is on mute. maybe your line is on mute

Speaker 7: Sorry, guys. That should be better now. Apologies. Good morning. Good morning, Gavin, and welcome to the company, and thanks Anders for taking the call. Two questions from my side, please. The first one relates, will probably be for Gavin Wood and relates to your arrival as new CEO of the company. Maybe just to help investors, if you maybe had to name your top three strategic priorities for the first 12, 18 months at the firm, what would they be? Maybe also which parts of the Impact4 strategic plan do you think might need a revision, if any? The second question is more on the current trends in Wound & Tissue Repair, which obviously has been hurt in Q2. Sorry, guys. sorry guys That should be better now. that should be better now Apologies. apologies Good morning. good morning Good morning, Gavin, and welcome to the company, and thanks Anders for taking the call. good morning gavin and welcome to the company and thanks anders for taking the call Two questions from my side, please. two questions from my side please The first one relates, will probably be for Gavin Wood and relates to your arrival as new CEO of the company. the first one relates will probably be for gavin wood and relates to your arrival as new ceo of the company Maybe just to help investors, if you maybe had to name your top three strategic priorities for the first 12, 18 months at the firm, what would they be? maybe just to help investors if you maybe had to name your top three strategic priorities for the first 12 18 months at the firm what would they be Maybe also which parts of the Impact4 strategic plan do you think might need a revision, if any? maybe also which parts of the impact4 strategic plan do you think might need a revision if any The second question is more on the current trends in Wound & Tissue Repair, which obviously has been hurt in Q2. the second question is more on the current trends in wound & tissue repair which obviously has been hurt in q2 What have you seen as into the third quarter? Have you seen any difference in the performance for either Kerecis or for the rest of the business in especially in Europe? Thank you. What have you seen as into the third quarter? what have you seen as into the third quarter Have you seen any difference in the performance for either Kerecis or for the rest of the business in especially in Europe? have you seen any difference in the performance for either kerecis or for the rest of the business in especially in europe Thank you. thank you

Speaker 2: Julien, thanks a lot for your two questions. Let me take the second question and then Gavin will come back on question number one. To your second question around the current trend on our Wound & Tissue Repair. As we have been talking about at length, we revised our full year guidance to the organic growth of 5%-6%. That was driven by the Biologics business in the U.S. as we delivered around 0% growth here in the second quarter. We are expecting to be at that level or slightly below 0% for the rest of the year. That is the main driver of the revised guidance that we did two to three weeks ago. Julien, thanks a lot for your two questions. julien thanks a lot for your two questions Let me take the second question and then Gavin will come back on question number one. let me take the second question and then gavin will come back on question number one To your second question around the current trend on our Wound & Tissue Repair. to your second question around the current trend on our wound & tissue repair As we have been talking about at length, we revised our full year guidance to the organic growth of 5%-6%. as we have been talking about at length we revised our full year guidance to the organic growth of 5%-6% That was driven by the Biologics business in the U.S. as we delivered around 0% growth here in the second quarter. that was driven by the biologics business in the u.s as we delivered around 0% growth here in the second quarter We are expecting to be at that level or slightly below 0% for the rest of the year. we are expecting to be at that level or slightly below 0% for the rest of the year That is the main driver of the revised guidance that we did two to three weeks ago. that is the main driver of the revised guidance that we did two to three weeks ago We have also, as I just mentioned, seen some slowdown here in Europe on the dressing side, in particular in France, and to some extent also in Germany, driven by price reforms. That's how we see it and that's what we are looking into for the second half of this financial year. Gavin? We have also, as I just mentioned, seen some slowdown here in Europe on the dressing side, in particular in France, and to some extent also in Germany, driven by price reforms. we have also as i just mentioned seen some slowdown here in europe on the dressing side in particular in france and to some extent also in germany driven by price reforms That's how we see it and that's what we are looking into for the second half of this financial year. that's how we see it and that's what we are looking into for the second half of this financial year Gavin? gavin

Speaker 4: Thank you, Julien, for the, for the kind welcome and my first question. Maybe let me start by sharing a little bit about some of the things that I will bring to Coloplast, then I'll answer your question about priorities and my perspective on Impact4. I think the first thing for all investors and analysts that are listening, you know, I've come from a lot of broad medtech experience, you know, leading large global multi-billion dollar medtech businesses. I've had the opportunity to see all the various priorities across medtech, and I've operated at scale across multiple franchises and geographies and organizations where, you know, we tend to focus on consistency, clarity, and accountability matters each and every day. Thank you, Julien, for the, for the kind welcome and my first question. thank you julien for the for the kind welcome and my first question Maybe let me start by sharing a little bit about some of the things that I will bring to Coloplast, then I'll answer your question about priorities and my perspective on Impact4. maybe let me start by sharing a little bit about some of the things that i will bring to coloplast then i'll answer your question about priorities and my perspective on impact4 I think the first thing for all investors and analysts that are listening, you know, I've come from a lot of broad medtech experience, you know, leading large global multi-billion dollar medtech businesses. i think the first thing for all investors and analysts that are listening you know i've come from a lot of broad medtech experience you know leading large global multi-billion dollar medtech businesses I've had the opportunity to see all the various priorities across medtech, and I've operated at scale across multiple franchises and geographies and organizations where, you know, we tend to focus on consistency, clarity, and accountability matters each and every day. i've had the opportunity to see all the various priorities across medtech and i've operated at scale across multiple franchises and geographies and organizations where you know we tend to focus on consistency clarity and accountability matters each and every day This experience has helped shaped how I think about, you know, driving leadership at scale and how to keep priorities really clear with decision-making that's disciplined and execution that's predictable as organizations grow and become larger. I also, you know, also bring a background in wound care from my days at Mölnlycke across from the other areas that I've mentioned. The second area, Julien, is really around leadership and talent. I think in large organizations, outcomes ultimately depend on the leaders that you put in critical roles and the standards that you set for them, so I'm gonna be spending a lot of time here. I've spent many years building leadership teams and developing talent, which I'm incredibly passionate about, and creating environments where people are both, you know, empowered but also held accountable for clear expectations and results. This experience has helped shaped how I think about, you know, driving leadership at scale and how to keep priorities really clear with decision-making that's disciplined and execution that's predictable as organizations grow and become larger. this experience has helped shaped how i think about you know driving leadership at scale and how to keep priorities really clear with decision-making that's disciplined and execution that's predictable as organizations grow and become larger I also, you know, also bring a background in wound care from my days at Mölnlycke across from the other areas that I've mentioned. i also you know also bring a background in wound care from my days at mölnlycke across from the other areas that i've mentioned The second area, Julien, is really around leadership and talent. the second area julien is really around leadership and talent I think in large organizations, outcomes ultimately depend on the leaders that you put in critical roles and the standards that you set for them, so I'm gonna be spending a lot of time here. i think in large organizations outcomes ultimately depend on the leaders that you put in critical roles and the standards that you set for them so i'm gonna be spending a lot of time here I've spent many years building leadership teams and developing talent, which I'm incredibly passionate about, and creating environments where people are both, you know, empowered but also held accountable for clear expectations and results. i've spent many years building leadership teams and developing talent which i'm incredibly passionate about and creating environments where people are both you know empowered but also held accountable for clear expectations and results I think it's ultimately about instilling an ownership mindset across your entire leadership organization. I think that the third thing is I'm bringing, you know, deep experience across both Europe and U.S. I've spent a lot of my career in, you know, both continents, North America and Europe, and having the opportunity to lead innovation in a lot of, you know, global execution roles. I think that this is something that I bring that also reinforces the speed of execution, being able to see multiple geographies and different ways of doing things, sustain commercial intensity and credibility, building credibility with clinicians over time, and working in different environments and environments that establish, you know, a very clear benchmark for urgency, focus and leadership, and that's something I'm going to be looking towards. I think it's ultimately about instilling an ownership mindset across your entire leadership organization. i think it's ultimately about instilling an ownership mindset across your entire leadership organization I think that the third thing is I'm bringing, you know, deep experience across both Europe and U.S. i think that the third thing is i'm bringing you know deep experience across both europe and u.s I've spent a lot of my career in, you know, both continents, North America and Europe, and having the opportunity to lead innovation in a lot of, you know, global execution roles. i've spent a lot of my career in you know both continents north america and europe and having the opportunity to lead innovation in a lot of you know global execution roles I think that this is something that I bring that also reinforces the speed of execution, being able to see multiple geographies and different ways of doing things, sustain commercial intensity and credibility, building credibility with clinicians over time, and working in different environments and environments that establish, you know, a very clear benchmark for urgency, focus and leadership, and that's something I'm going to be looking towards. i think that this is something that i bring that also reinforces the speed of execution being able to see multiple geographies and different ways of doing things sustain commercial intensity and credibility building credibility with clinicians over time and working in different environments and environments that establish you know a very clear benchmark for urgency focus and leadership and that's something i'm going to be looking towards The last thing I just wanna share on background, and then I'm gonna get into a few of your specific questions, is I think commercial experience that's grounded in the front line is something that's needed at this point. I started my career in sales, and I've stayed close to the field throughout. This matters to me because it always gives you a very direct understanding of how trust is built with customers, how adoption really happens with products and technology, and what makes execution work in practice. I genuinely enjoy spending time with the frontline teams and customers because that's where you really truly learn how an organization's working, and I'm gonna be doing a lot more of that. To answer your question directly on my approach then for priorities, I'm really on a listening tour. The last thing I just wanna share on background, and then I'm gonna get into a few of your specific questions, is I think commercial experience that's grounded in the front line is something that's needed at this point. the last thing i just wanna share on background and then i'm gonna get into a few of your specific questions is i think commercial experience that's grounded in the front line is something that's needed at this point I started my career in sales, and I've stayed close to the field throughout. i started my career in sales and i've stayed close to the field throughout This matters to me because it always gives you a very direct understanding of how trust is built with customers, how adoption really happens with products and technology, and what makes execution work in practice. this matters to me because it always gives you a very direct understanding of how trust is built with customers how adoption really happens with products and technology and what makes execution work in practice I genuinely enjoy spending time with the frontline teams and customers because that's where you really truly learn how an organization's working, and I'm gonna be doing a lot more of that. i genuinely enjoy spending time with the frontline teams and customers because that's where you really truly learn how an organization's working and i'm gonna be doing a lot more of that To answer your question directly on my approach then for priorities, I'm really on a listening tour. to answer your question directly on my approach then for priorities i'm really on a listening tour Right now, like, my focus is getting closer to the business, getting to know our teams, our people, our users, our customers, and then I'm gonna form my perspective on the value drivers that will enable us to deliver on our ambition. You can think of that as a listening tour. If I think of the direction of Impact4, you know, what you asked specifically, it's really more my role is to create the environment to unlock the potential for our teams to really excel and execute. If you look at Impact4, it's founded on four principles, you know, driving growth, you know, through innovative customer offerings. That's innovation. I mean, that resonates with me. You know, unlocking next-level efficiency gains and operational efficiency, that's super important to keep a company strong long term. Right now, like, my focus is getting closer to the business, getting to know our teams, our people, our users, our customers, and then I'm gonna form my perspective on the value drivers that will enable us to deliver on our ambition. right now like my focus is getting closer to the business getting to know our teams our people our users our customers and then i'm gonna form my perspective on the value drivers that will enable us to deliver on our ambition You can think of that as a listening tour. you can think of that as a listening tour If I think of the direction of Impact4, you know, what you asked specifically, it's really more my role is to create the environment to unlock the potential for our teams to really excel and execute. if i think of the direction of impact4 you know what you asked specifically it's really more my role is to create the environment to unlock the potential for our teams to really excel and execute If you look at Impact4, it's founded on four principles, you know, driving growth, you know, through innovative customer offerings. if you look at impact4 it's founded on four principles you know driving growth you know through innovative customer offerings That's innovation. that's innovation I mean, that resonates with me. i mean that resonates with me You know, unlocking next-level efficiency gains and operational efficiency, that's super important to keep a company strong long term. you know unlocking next-level efficiency gains and operational efficiency that's super important to keep a company strong long term Embracing technology, you know, through tech and AI is gonna be a key enabler for all medtech companies over the next five to ten years to transform. Finally, you know, cultivating a winning and sustainable company. This is really about driving culture and the talent engine. If there's one area that I'm probably gonna particularly lean into, not change, I'm gonna spend a lot of time on really understanding the culture and the talent and the high performance across Coloplast because I believe that organizations that win long term in medtech, they win because they have a winning culture and a talent engine built for the future. Thank you for the question. Embracing technology, you know, through tech and AI is gonna be a key enabler for all medtech companies over the next five to ten years to transform. embracing technology you know through tech and ai is gonna be a key enabler for all medtech companies over the next five to ten years to transform Finally, you know, cultivating a winning and sustainable company. finally you know cultivating a winning and sustainable company This is really about driving culture and the talent engine. this is really about driving culture and the talent engine If there's one area that I'm probably gonna particularly lean into, not change, I'm gonna spend a lot of time on really understanding the culture and the talent and the high performance across Coloplast because I believe that organizations that win long term in medtech, they win because they have a winning culture and a talent engine built for the future. if there's one area that i'm probably gonna particularly lean into not change i'm gonna spend a lot of time on really understanding the culture and the talent and the high performance across coloplast because i believe that organizations that win long term in medtech they win because they have a winning culture and a talent engine built for the future Thank you for the question. thank you for the question

Speaker 7: Thank you very much, and good luck. Thank you very much, and good luck. thank you very much and good luck

Speaker 10: The next question comes from the line of Doyle Graham from UBS. Please go ahead. The next question comes from the line of Doyle Graham from UBS. the next question comes from the line of doyle graham from ubs Please go ahead. please go ahead

Speaker 5: Morning. Thanks, guys. Thanks for taking my questions. Gavin, let me take a couple for you, which is, firstly, just on, it's sort of follow-up to Julien's question, but maybe a little bit more specific, which if you look at the Coloplast share price, it's obviously been a disappointing share price for the last two, three years. When you think about what creates most value to the things that you can do, what metrics specifically are you focused on, just holistically, regardless of whether it's Coloplast or just when you look at a business in your prior experience, is it organic growth? Is it return on invested capital? Is it margin, EPS? What do you think is the one metric that you're kind of most focused on that can kind of move the dial? Morning. morning Thanks, guys. thanks guys Thanks for taking my questions. thanks for taking my questions Gavin, let me take a couple for you, which is, firstly, just on, it's sort of follow-up to Julien's question, but maybe a little bit more specific, which if you look at the Coloplast share price, it's obviously been a disappointing share price for the last two, three years. gavin let me take a couple for you which is firstly just on it's sort of follow-up to julien's question but maybe a little bit more specific which if you look at the coloplast share price it's obviously been a disappointing share price for the last two, three years When you think about what creates most value to the things that you can do, what metrics specifically are you focused on, just holistically, regardless of whether it's Coloplast or just when you look at a business in your prior experience, is it organic growth? when you think about what creates most value to the things that you can do what metrics specifically are you focused on just holistically regardless of whether it's coloplast or just when you look at a business in your prior experience is it organic growth Is it return on invested capital? is it return on invested capital Is it margin, EPS? is it margin eps What do you think is the one metric that you're kind of most focused on that can kind of move the dial? what do you think is the one metric that you're kind of most focused on that can kind of move the dial Maybe secondly, you talked about being in sort of prospective gathering mode. How long would you anticipate that taking? Thank you. Maybe secondly, you talked about being in sort of prospective gathering mode. maybe secondly you talked about being in sort of prospective gathering mode How long would you anticipate that taking? how long would you anticipate that taking Thank you. thank you

Speaker 4: Thank you for the question. Just for context, I just wanna be very, you know, direct with everyone. I'm less than two weeks in role, and clearly I'm still forming opinions and it's gonna take me some time to learn. I think, you know, pragmatically, I'm gonna need, you know, 90 days to really do this listening tour and learn and start to form some opinions where I can come back and share thoughts. This is what I can share right now. I think, you know, Coloplast has this admirable, you know, company and a great legacy that is incredibly strong. This is what attracted me to the organization. I'm really looking forward to getting into the business and getting to know the company at a deeper level. Thank you for the question. thank you for the question Just for context, I just wanna be very, you know, direct with everyone. just for context i just wanna be very you know direct with everyone I'm less than two weeks in role, and clearly I'm still forming opinions and it's gonna take me some time to learn. i'm less than two weeks in role and clearly i'm still forming opinions and it's gonna take me some time to learn I think, you know, pragmatically, I'm gonna need, you know, 90 days to really do this listening tour and learn and start to form some opinions where I can come back and share thoughts. i think you know pragmatically i'm gonna need you know 90 days to really do this listening tour and learn and start to form some opinions where i can come back and share thoughts This is what I can share right now. this is what i can share right now I think, you know, Coloplast has this admirable, you know, company and a great legacy that is incredibly strong. i think you know coloplast has this admirable you know company and a great legacy that is incredibly strong This is what attracted me to the organization. this is what attracted me to the organization I'm really looking forward to getting into the business and getting to know the company at a deeper level. i'm really looking forward to getting into the business and getting to know the company at a deeper level I'm getting, you know, getting to know the people, the leadership teams, the users, the customers. Over, you know, this next 90 days, this is gonna help me form my perspective on the value drivers that will enable us to deliver on our ambition. I think, you know, to be fair to you, the one area that I always think you lean in on is people. It's talent. Like, if you're saying, "What's the one metric?" You have to get the teams right. That, to me, is going to be the unlock in the future for everything. If you get the right people in the right roles, you get them engaged and motivated, you get them believing in the strategy, you get them believing in a winning culture, anything is possible. Thank you for the question. I'm getting, you know, getting to know the people, the leadership teams, the users, the customers. i'm getting you know getting to know the people the leadership teams the users the customers Over, you know, this next 90 days, this is gonna help me form my perspective on the value drivers that will enable us to deliver on our ambition. over you know this next 90 days this is gonna help me form my perspective on the value drivers that will enable us to deliver on our ambition I think, you know, to be fair to you, the one area that I always think you lean in on is people. i think you know to be fair to you the one area that i always think you lean in on is people It's talent. it's talent Like, if you're saying, "What's the one metric?" You have to get the teams right. like if you're saying "what's the one metric?" you have to get the teams right That, to me, is going to be the unlock in the future for everything. that to me is going to be the unlock in the future for everything If you get the right people in the right roles, you get them engaged and motivated, you get them believing in the strategy, you get them believing in a winning culture, anything is possible. if you get the right people in the right roles you get them engaged and motivated you get them believing in the strategy you get them believing in a winning culture anything is possible Thank you for the question. thank you for the question

Speaker 5: I need to just follow up then, just because I think people would like maybe something more concrete on that, which it's not to sort of hold you to anything, but again, it seems pretty reasonable just to. When you come in and look at the business, any business, what do you think is the best signifier of value creation? It's gonna be hard to measure culture, but we can measure return on invested capital. We can measure organic growth. Obviously for the last years that have come past, there's been different focuses. It's just generally to get a sense of when you come in and when you assess the business to start with, which were the things financially that you thought were attractive and could be enhanced? I need to just follow up then, just because I think people would like maybe something more concrete on that, which it's not to sort of hold you to anything, but again, it seems pretty reasonable just to. i need to just follow up then just because i think people would like maybe something more concrete on that which it's not to sort of hold you to anything but again it seems pretty reasonable just to When you come in and look at the business, any business, what do you think is the best signifier of value creation? when you come in and look at the business any business what do you think is the best signifier of value creation It's gonna be hard to measure culture, but we can measure return on invested capital. it's gonna be hard to measure culture but we can measure return on invested capital We can measure organic growth. we can measure organic growth Obviously for the last years that have come past, there's been different focuses. obviously for the last years that have come past there's been different focuses It's just generally to get a sense of when you come in and when you assess the business to start with, which were the things financially that you thought were attractive and could be enhanced? it's just generally to get a sense of when you come in and when you assess the business to start with which were the things financially that you thought were attractive and could be enhanced

Speaker 4: For me, you know, if I give something more concrete, it would be focusing on value creation. If there's one area that I typically look at from a strong commercial background, it's commercial execution. For me, you know, if I give something more concrete, it would be focusing on value creation. for me you know if i give something more concrete it would be focusing on value creation If there's one area that I typically look at from a strong commercial background, it's commercial execution. if there's one area that i typically look at from a strong commercial background it's commercial execution

Speaker 5: Okay. Okay. That's all right. Thank you. Okay. okay Okay. okay That's all right. that's all right Thank you. thank you

Speaker 10: The next question comes from the line of Aisyah Noor from Morgan Stanley. Please go ahead. The next question comes from the line of Aisyah Noor from Morgan Stanley. the next question comes from the line of aisyah noor from morgan stanley Please go ahead. please go ahead

Speaker 1: Hi. Good morning, everyone, and thanks for taking my question, and good to virtually meet you as well, Gavin. My first question as well is also for Gavin. It relates to your approach to innovation and R&D. Coloplast as an organization has a lot of projects underway, like Luja and Intibia. As you look at the organization today, do you see the current level of R&D investment as adequate, or do you think there's scope to raise that to kind of take the portfolio to a more competitive level? Then I have a financial follow-up for Anders after. Thank you. Hi. hi Good morning, everyone, and thanks for taking my question, and good to virtually meet you as well, Gavin. good morning everyone and thanks for taking my question and good to virtually meet you as well gavin My first question as well is also for Gavin. my first question as well is also for gavin It relates to your approach to innovation and R&D. it relates to your approach to innovation and r&d Coloplast as an organization has a lot of projects underway, like Luja and Intibia. coloplast as an organization has a lot of projects underway like luja and intibia As you look at the organization today, do you see the current level of R&D investment as adequate, or do you think there's scope to raise that to kind of take the portfolio to a more competitive level? as you look at the organization today do you see the current level of r&d investment as adequate or do you think there's scope to raise that to kind of take the portfolio to a more competitive level Then I have a financial follow-up for Anders after. then i have a financial follow-up for anders after Thank you. thank you

Speaker 4: Thank you for the question. You know, first, you know, I certainly don't want to keep repeating myself. I am less than two weeks in. What I can share is innovation's important. There's absolutely no question. You know, I'm very happy to be very open with you with the innovation that Coloplast has started to put out, and I'm also very deeply committed to innovation going forward. The reality is it's still early days for me to give you a full assessment. You know, what I see in this organization is an organization that's innovation driven. Thank you for the question. thank you for the question You know, first, you know, I certainly don't want to keep repeating myself. you know first you know i certainly don't want to keep repeating myself I am less than two weeks in. i am less than two weeks in What I can share is innovation's important. what i can share is innovation's important There's absolutely no question. there's absolutely no question You know, I'm very happy to be very open with you with the innovation that Coloplast has started to put out, and I'm also very deeply committed to innovation going forward. you know i'm very happy to be very open with you with the innovation that coloplast has started to put out and i'm also very deeply committed to innovation going forward The reality is it's still early days for me to give you a full assessment. the reality is it's still early days for me to give you a full assessment You know, what I see in this organization is an organization that's innovation driven. you know what i see in this organization is an organization that's innovation driven It's been embedded in the company's DNA for a long time, has a strong purpose and mission, and it's clear when you meet our people and when I've met with the R&D teams, what makes people proud working at Coloplast is the difference that they make with innovative products that has a meaningful impact on users. I think what's also clear is this has allowed Coloplast to maintain a number of number one global market leading positions in their products and innovation. Without those, we certainly wouldn't be where we are today. You know, I will finish saying that as a newcomer to the company, I'm excited to start to build my own perspective on what the future holds for Coloplast. I'm excited about where we can take innovation. It's been embedded in the company's DNA for a long time, has a strong purpose and mission, and it's clear when you meet our people and when I've met with the R&D teams, what makes people proud working at Coloplast is the difference that they make with innovative products that has a meaningful impact on users. it's been embedded in the company's dna for a long time has a strong purpose and mission and it's clear when you meet our people and when i've met with the r&d teams what makes people proud working at coloplast is the difference that they make with innovative products that has a meaningful impact on users I think what's also clear is this has allowed Coloplast to maintain a number of number one global market leading positions in their products and innovation. i think what's also clear is this has allowed coloplast to maintain a number of number one global market leading positions in their products and innovation Without those, we certainly wouldn't be where we are today. without those we certainly wouldn't be where we are today You know, I will finish saying that as a newcomer to the company, I'm excited to start to build my own perspective on what the future holds for Coloplast. you know i will finish saying that as a newcomer to the company i'm excited to start to build my own perspective on what the future holds for coloplast I'm excited about where we can take innovation. i'm excited about where we can take innovation To answer your question, I'm really excited about some of the attractive assets that we have, like Luja, like Intibia, like Biologics. I think that what we're gonna see is more innovation coming out in these lines in the years to come that's gonna keep Coloplast strong and keep Coloplast innovative. Thank you for the question. To answer your question, I'm really excited about some of the attractive assets that we have, like Luja, like Intibia, like Biologics. to answer your question i'm really excited about some of the attractive assets that we have like luja like intibia like biologics I think that what we're gonna see is more innovation coming out in these lines in the years to come that's gonna keep Coloplast strong and keep Coloplast innovative. i think that what we're gonna see is more innovation coming out in these lines in the years to come that's gonna keep coloplast strong and keep coloplast innovative Thank you for the question. thank you for the question

Speaker 1: Thanks a lot. My follow-up for Anders is, I guess one on profitability and margins. Can you just provide for us your assumptions on the cost inflation for raw materials in the second half, and how much safety inventory you have before this inflation headwind starts to kick in? Thank you. Thanks a lot. thanks a lot My follow-up for Anders is, I guess one on profitability and margins. my follow-up for anders is i guess one on profitability and margins Can you just provide for us your assumptions on the cost inflation for raw materials in the second half, and how much safety inventory you have before this inflation headwind starts to kick in? can you just provide for us your assumptions on the cost inflation for raw materials in the second half and how much safety inventory you have before this inflation headwind starts to kick in Thank you. thank you

Speaker 2: Yeah, let me take that one. Thanks. We also got this question at our call three weeks ago. We are following the Middle East situation very closely. We, as you know, we have around 50% of our cost of goods sold, that's raw materials. In the first half of this year, the inflation levels, raw material prices were around flattish. We have not seen any impact yet, but I am expecting some impact into the towards the end of this year, so in Q4. Right now, I'm assuming around a 1% impact on our raw materials. That is, of course, under the assumption that the conflict will end soon. We are also seeing a little bit of impact right now on our logistics costs. Yeah, let me take that one. yeah let me take that one Thanks. thanks We also got this question at our call three weeks ago. we also got this question at our call three weeks ago We are following the Middle East situation very closely. we are following the middle east situation very closely We, as you know, we have around 50% of our cost of goods sold, that's raw materials. we as you know we have around 50% of our cost of goods sold that's raw materials In the first half of this year, the inflation levels, raw material prices were around flattish. in the first half of this year the inflation levels raw material prices were around flattish We have not seen any impact yet, but I am expecting some impact into the towards the end of this year, so in Q4. we have not seen any impact yet but i am expecting some impact into the towards the end of this year so in q4 Right now, I'm assuming around a 1% impact on our raw materials. right now i'm assuming around a 1% impact on our raw materials That is, of course, under the assumption that the conflict will end soon. that is of course under the assumption that the conflict will end soon We are also seeing a little bit of impact right now on our logistics costs. we are also seeing a little bit of impact right now on our logistics costs On the energy side, we are hedged, and we are not expecting anything there. My assumption right now is around 1% increase coming into our Q4, based on the current knowledge about the Middle East. On the energy side, we are hedged, and we are not expecting anything there. on the energy side we are hedged and we are not expecting anything there My assumption right now is around 1% increase coming into our Q4, based on the current knowledge about the Middle East. my assumption right now is around 1% increase coming into our q4 based on the current knowledge about the middle east

Speaker 1: Got it. Thank you so much. Got it. got it Thank you so much. thank you so much

Speaker 10: The next question comes from the line of Anna Ratcliffe from Bank of America. Please go ahead. The next question comes from the line of Anna Ratcliffe from Bank of America. the next question comes from the line of anna ratcliffe from bank of america Please go ahead. please go ahead

Speaker 3: Hi. Good morning, and thank you for taking the questions. Gavin, congratulations on the new role. Appreciate your commentary that you're only two weeks in, but I wanted to ask, as you get under the hood, what are your first impressions of the business? What drew you most to the role, and how are you thinking about the different Hi. hi Good morning, and thank you for taking the questions. good morning and thank you for taking the questions Gavin, congratulations on the new role. gavin congratulations on the new role Appreciate your commentary that you're only two weeks in, but I wanted to ask, as you get under the hood, what are your first impressions of the business? appreciate your commentary that you're only two weeks in but i wanted to ask as you get under the hood what are your first impressions of the business What drew you most to the role, and how are you thinking about the different what drew you most to the role and how are you thinking about the different Strengths and opportunities, and then maybe for Anders, I wanted to ask to dig a little bit into Interventional Urology and that high single-digit growth for this year. How sustainable is that going forward? How much of that is driven by easy comps from the recall last year? Any update you could give us on the Intibia launch timing would be helpful. Thanks again for taking the questions. Strengths and opportunities, and then maybe for Anders, I wanted to ask to dig a little bit into Interventional Urology and that high single-digit growth for this year. strengths and opportunities and then maybe for anders i wanted to ask to dig a little bit into interventional urology and that high single-digit growth for this year How sustainable is that going forward? how sustainable is that going forward How much of that is driven by easy comps from the recall last year? how much of that is driven by easy comps from the recall last year Any update you could give us on the Intibia launch timing would be helpful. any update you could give us on the intibia launch timing would be helpful Thanks again for taking the questions. thanks again for taking the questions

Speaker 4: Thanks, Anna. Thank you for the warm welcome. You know, maybe let me start with your question on why Coloplast and what excites me and then what have I, you know, seen in the first week and a half. I'll reiterate what I shared earlier. I think the big thing is the purpose. Like, it really excited me. Coming from an organization like Johnson & Johnson, which has a strong credo, coming into an organization like Coloplast, where you see something similar with this purpose-led organization, where you're trying to develop solutions for users and patients that really need to find a technology, this was extremely motivating for me, especially when you're actually being able to combine innovation to improving patient outcomes. Thanks, Anna. thanks anna Thank you for the warm welcome. thank you for the warm welcome You know, maybe let me start with your question on why Coloplast and what excites me and then what have I, you know, seen in the first week and a half. you know maybe let me start with your question on why coloplast and what excites me and then what have i you know seen in the first week and a half I'll reiterate what I shared earlier. i'll reiterate what i shared earlier I think the big thing is the purpose. i think the big thing is the purpose Like, it really excited me. like it really excited me Coming from an organization like Johnson & Johnson, which has a strong credo, coming into an organization like Coloplast, where you see something similar with this purpose-led organization, where you're trying to develop solutions for users and patients that really need to find a technology, this was extremely motivating for me, especially when you're actually being able to combine innovation to improving patient outcomes. coming from an organization like johnson & johnson which has a strong credo coming into an organization like coloplast where you see something similar with this purpose-led organization where you're trying to develop solutions for users and patients that really need to find a technology this was extremely motivating for me especially when you're actually being able to combine innovation to improving patient outcomes The second, and I'll say it again, it's really the people. I had a chance through the process to meet more than just the board. You know, people that work at Coloplast have a deep connection. There's something special about this company that it's not just about talent and passion. They're deeply committed. This is something that motivated me. When you can work with an organization where people have a strong purpose, they put a lot of emphasis on building strong teams, and they work together collaboratively, and where you feel there's a lot of talent that you can develop, I think that's something that you can make an organization a lot better long term. The last thing was really around the ambition. I think Coloplast is very sincere. The second, and I'll say it again, it's really the people. the second and i'll say it again it's really the people I had a chance through the process to meet more than just the board. i had a chance through the process to meet more than just the board You know, people that work at Coloplast have a deep connection. you know people that work at coloplast have a deep connection There's something special about this company that it's not just about talent and passion. there's something special about this company that it's not just about talent and passion They're deeply committed. they're deeply committed This is something that motivated me. this is something that motivated me When you can work with an organization where people have a strong purpose, they put a lot of emphasis on building strong teams, and they work together collaboratively, and where you feel there's a lot of talent that you can develop, I think that's something that you can make an organization a lot better long term. when you can work with an organization where people have a strong purpose they put a lot of emphasis on building strong teams and they work together collaboratively and where you feel there's a lot of talent that you can develop i think that's something that you can make an organization a lot better long term The last thing was really around the ambition. the last thing was really around the ambition I think Coloplast is very sincere. i think coloplast is very sincere We wanna write this next chapter. Part of that chapter is clear and in the Impact4, and part of that chapter is still to be written. I think as a new CEO, this is what makes me super motivated to be here, that you've got a balance of, you know, a great foundation of strength and opportunities to build for the future. I think, you know, maybe to answer, you know, your question about what I'm seeing, there's a lot of pride in this organization. That's something that I saw, you know, even from I mean, I've been walking the halls now for six, seven days. People are proud here. They really believe in the purpose of Coloplast, and that's a superpower to me. We wanna write this next chapter. we wanna write this next chapter Part of that chapter is clear and in the Impact4, and part of that chapter is still to be written. part of that chapter is clear and in the impact4 and part of that chapter is still to be written I think as a new CEO, this is what makes me super motivated to be here, that you've got a balance of, you know, a great foundation of strength and opportunities to build for the future. i think as a new ceo this is what makes me super motivated to be here that you've got a balance of you know a great foundation of strength and opportunities to build for the future I think, you know, maybe to answer, you know, your question about what I'm seeing, there's a lot of pride in this organization. i think you know maybe to answer you know your question about what i'm seeing there's a lot of pride in this organization That's something that I saw, you know, even from I mean, I've been walking the halls now for six, seven days. that's something that i saw you know even from i mean i've been walking the halls now for six seven days People are proud here. people are proud here They really believe in the purpose of Coloplast, and that's a superpower to me. they really believe in the purpose of coloplast and that's a superpower to me I also feel that there's an excitement from the organization on what they can build for the future through Impact4, especially around innovation. We talked a little bit about that. I think that there's going to be some great opportunities for us to innovate in the future. You know, finally, you know, people wanna be developed, and I think that that's in all organizations. I came from an organization that was deeply committed to developing talent. I'm excited to be here, and I see that there is an organization that wants to be developed. And that's exceptionally important in a medtech organization. Thank you for the question. I also feel that there's an excitement from the organization on what they can build for the future through Impact4, especially around innovation. i also feel that there's an excitement from the organization on what they can build for the future through impact4 especially around innovation We talked a little bit about that. we talked a little bit about that I think that there's going to be some great opportunities for us to innovate in the future. i think that there's going to be some great opportunities for us to innovate in the future You know, finally, you know, people wanna be developed, and I think that that's in all organizations. you know finally you know people wanna be developed and i think that that's in all organizations I came from an organization that was deeply committed to developing talent. i came from an organization that was deeply committed to developing talent I'm excited to be here, and I see that there is an organization that wants to be developed. i'm excited to be here and i see that there is an organization that wants to be developed And that's exceptionally important in a medtech organization. and that's exceptionally important in a medtech organization Thank you for the question. thank you for the question

Speaker 2: All right. Thanks, Gavin. To your second question around Urology, as mentioned earlier, our Urology business is really off to a good start. We have been growing around 8% in the two first quarters of this year, it is actually better than we had anticipated. We are expecting to keep this momentum for the remaining part of this year. It's really driven by our Men's Health business in the U.S. We continue to see a double-digit growth within our Men's Health. That's one thing. The second thing is that here in Europe, we are now recovering back from the recall we had last year. That is also impacting our Urology business, in particular here in Europe. All right. all right Thanks, Gavin. thanks gavin To your second question around Urology, as mentioned earlier, our Urology business is really off to a good start. to your second question around urology as mentioned earlier our urology business is really off to a good start We have been growing around 8% in the two first quarters of this year, it is actually better than we had anticipated. we have been growing around 8% in the two first quarters of this year it is actually better than we had anticipated We are expecting to keep this momentum for the remaining part of this year. we are expecting to keep this momentum for the remaining part of this year It's really driven by our Men's Health business in the U.S. it's really driven by our men's health business in the u.s We continue to see a double-digit growth within our Men's Health. we continue to see a double-digit growth within our men's health That's one thing. that's one thing The second thing is that here in Europe, we are now recovering back from the recall we had last year. the second thing is that here in europe we are now recovering back from the recall we had last year That is also impacting our Urology business, in particular here in Europe. that is also impacting our urology business in particular here in europe To your question around Intibia, that process is running. We are expecting to get approval later this year in order to launch the solution in the first six months of next financial year. It's following the plan we have laid out. That's the update on Urology. To your question around Intibia, that process is running. to your question around intibia that process is running We are expecting to get approval later this year in order to launch the solution in the first six months of next financial year. we are expecting to get approval later this year in order to launch the solution in the first six months of next financial year It's following the plan we have laid out. it's following the plan we have laid out That's the update on Urology. that's the update on urology

Speaker 10: The next question comes from the line of Veronika Dubajova from Citi. Please go ahead. The next question comes from the line of Veronika Dubajova from Citi. the next question comes from the line of veronika dubajova from citi Please go ahead. please go ahead

Speaker 11: Good morning, thank you for taking my questions. I have two, please. First of all, Gavin, welcome, and look forward to interacting with you going forward. My first question is for you. I guess I gotta try to ask this a little bit differently, but I think Graham made a very important point. Looking at the Coloplast share price, it has been a very meaningful underperformer versus the rest of the sector. You know, normally in situations like that, when a CEO is arriving, it is with a mandate to fix a bunch of problems. I'm curious whether you feel that, you know, this is a mandate that has been afforded to you by the board or not, and whether this is something that you are actively thinking about. Good morning, thank you for taking my questions. good morning thank you for taking my questions I have two, please. i have two please First of all, Gavin, welcome, and look forward to interacting with you going forward. first of all gavin welcome and look forward to interacting with you going forward My first question is for you. my first question is for you I guess I gotta try to ask this a little bit differently, but I think Graham made a very important point. i guess i gotta try to ask this a little bit differently but i think graham made a very important point Looking at the Coloplast share price, it has been a very meaningful underperformer versus the rest of the sector. looking at the coloplast share price it has been a very meaningful underperformer versus the rest of the sector You know, normally in situations like that, when a CEO is arriving, it is with a mandate to fix a bunch of problems. you know normally in situations like that when a ceo is arriving it is with a mandate to fix a bunch of problems I'm curious whether you feel that, you know, this is a mandate that has been afforded to you by the board or not, and whether this is something that you are actively thinking about. i'm curious whether you feel that you know this is a mandate that has been afforded to you by the board or not and whether this is something that you are actively thinking about You know, obviously appreciate all the great things you've mentioned about Coloplast, clearly, you know, sometimes even great companies need help. Maybe if you can talk a little bit around how you're thinking about that, I think that would be super helpful for us to all understand. My second question is a follow-up on Aisyah's question around inflation, and Anders. I just want to make sure I understood your comments there. Are you assuming inflation picks up in the fourth quarter of the fiscal or the calendar year? And I guess 1% doesn't sound like a very big number, to be blunt. You know, if I go back to sort of the type of inflationary pressure that we saw back in 2022, 2023, it was running in the mid to high single digits. You know, obviously appreciate all the great things you've mentioned about Coloplast, clearly, you know, sometimes even great companies need help. you know obviously appreciate all the great things you've mentioned about coloplast clearly you know sometimes even great companies need help Maybe if you can talk a little bit around how you're thinking about that, I think that would be super helpful for us to all understand. maybe if you can talk a little bit around how you're thinking about that i think that would be super helpful for us to all understand My second question is a follow-up on Aisyah's question around inflation, and Anders. my second question is a follow-up on aisyah's question around inflation and anders I just want to make sure I understood your comments there. i just want to make sure i understood your comments there Are you assuming inflation picks up in the fourth quarter of the fiscal or the calendar year? And I guess 1% doesn't sound like a very big number, to be blunt. are you assuming inflation picks up in the fourth quarter of the fiscal or the calendar year? and i guess 1% doesn't sound like a very big number to be blunt You know, if I go back to sort of the type of inflationary pressure that we saw back in 2022, 2023, it was running in the mid to high single digits. you know if i go back to sort of the type of inflationary pressure that we saw back in 2022 2023 it was running in the mid to high single digits Just maybe help me contextualize that and why you think this is much less severe this time around. Maybe some sensitivity as we move to fiscal 2027, assuming the conflict is not resolved, might also be helpful. Thanks, guys. Just maybe help me contextualize that and why you think this is much less severe this time around. just maybe help me contextualize that and why you think this is much less severe this time around Maybe some sensitivity as we move to fiscal 2027, assuming the conflict is not resolved, might also be helpful. maybe some sensitivity as we move to fiscal 2027 assuming the conflict is not resolved might also be helpful Thanks, guys. thanks guys

Speaker 2: Thanks, Veronika. Let me take the second question, the inflation question first. What we are looking into, as I mentioned earlier, is that with the knowledge I have right now, we are looking at around 1% impact on our raw materials. That is going to impact us, as I said earlier, here in Q3, but in particular in our Q4 of this year. Depending on when the conflict is going to finish, there will be an impact into next year. When that is said, we are not at all looking into inflation levels at the levels we saw back in 2022 or 2023 with the knowledge I have today. Thanks, Veronika. thanks veronika Let me take the second question, the inflation question first. let me take the second question the inflation question first What we are looking into, as I mentioned earlier, is that with the knowledge I have right now, we are looking at around 1% impact on our raw materials. what we are looking into as i mentioned earlier is that with the knowledge i have right now we are looking at around 1% impact on our raw materials That is going to impact us, as I said earlier, here in Q3, but in particular in our Q4 of this year. that is going to impact us as i said earlier here in q3 but in particular in our q4 of this year Depending on when the conflict is going to finish, there will be an impact into next year. depending on when the conflict is going to finish there will be an impact into next year When that is said, we are not at all looking into inflation levels at the levels we saw back in 2022 or 2023 with the knowledge I have today. when that is said we are not at all looking into inflation levels at the levels we saw back in 2022 or 2023 with the knowledge i have today So that is by far not the levels we are looking into currently. The inflation is driven by, as you know, the higher oil price. Yes, we have some raw materials that are also impacted to some extent by the oil price, in particular injection molding chemicals. We are at least so far not looking into inflation levels as we saw in 2022. Gavin? So that is by far not the levels we are looking into currently. so that is by far not the levels we are looking into currently The inflation is driven by, as you know, the higher oil price. the inflation is driven by as you know the higher oil price Yes, we have some raw materials that are also impacted to some extent by the oil price, in particular injection molding chemicals. yes we have some raw materials that are also impacted to some extent by the oil price in particular injection molding chemicals We are at least so far not looking into inflation levels as we saw in 2022. we are at least so far not looking into inflation levels as we saw in 2022 Gavin? gavin

Speaker 4: Yes. Veronika, thank you for your question. You know, maybe let me try to answer it slightly differently. I'm a big believer that focus drives results and ultimately, you know, moving forward, the best way to improve Coloplast long term is to execute our strategy. The Impact4 strategy, it's all about setting the standard of care and becoming even more impactful towards our users, customers, and communities. A strategy is that's anchored in deep customer centricity, and this is one that resonates with me deeply as I shared earlier. I will say that I'm a builder at heart, and I do see something meaningful that we can achieve together as a company going forward. Yes. yes Veronika, thank you for your question. veronika thank you for your question You know, maybe let me try to answer it slightly differently. you know maybe let me try to answer it slightly differently I'm a big believer that focus drives results and ultimately, you know, moving forward, the best way to improve Coloplast long term is to execute our strategy. i'm a big believer that focus drives results and ultimately you know moving forward the best way to improve coloplast long term is to execute our strategy The Impact4 strategy, it's all about setting the standard of care and becoming even more impactful towards our users, customers, and communities. the impact4 strategy it's all about setting the standard of care and becoming even more impactful towards our users customers and communities A strategy is that's anchored in deep customer centricity, and this is one that resonates with me deeply as I shared earlier. a strategy is that's anchored in deep customer centricity and this is one that resonates with me deeply as i shared earlier I will say that I'm a builder at heart, and I do see something meaningful that we can achieve together as a company going forward. i will say that i'm a builder at heart and i do see something meaningful that we can achieve together as a company going forward That direction, you know, has been set, my focus now is really, you know, identifying on how we can unlock the potential and create an environment for value creation going forward. I think that the last thing that I would share is, you know, I need some time to form, you know, a clearer view. It's. I can sense also from the questions, you know, it's too early. I need time to form a clearer view of where the future growth opportunities may lie, then, you know, likely where we need to challenge ourself, you know, as we look ahead. Once I have that view, I'll be very open in sharing it. That direction, you know, has been set, my focus now is really, you know, identifying on how we can unlock the potential and create an environment for value creation going forward. that direction you know has been set my focus now is really you know identifying on how we can unlock the potential and create an environment for value creation going forward I think that the last thing that I would share is, you know, I need some time to form, you know, a clearer view. i think that the last thing that i would share is you know i need some time to form you know a clearer view It's. it's I can sense also from the questions, you know, it's too early. i can sense also from the questions you know it's too early I need time to form a clearer view of where the future growth opportunities may lie, then, you know, likely where we need to challenge ourself, you know, as we look ahead. i need time to form a clearer view of where the future growth opportunities may lie then you know likely where we need to challenge ourself you know as we look ahead Once I have that view, I'll be very open in sharing it. once i have that view i'll be very open in sharing it

Speaker 11: I appreciate that, Gavin. I guess the question for all of us is, you know, there is a strategy that doesn't seem to be yielding the results for a while now. I guess what, you know, all of us are trying to understand is to what extent are you ready to throw out the rule book and start from scratch? I'll put it bluntly, that's really, I think, what we're all trying to understand. I don't know if you can comment on that. I appreciate that, Gavin. i appreciate that gavin I guess the question for all of us is, you know, there is a strategy that doesn't seem to be yielding the results for a while now. i guess the question for all of us is you know there is a strategy that doesn't seem to be yielding the results for a while now I guess what, you know, all of us are trying to understand is to what extent are you ready to throw out the rule book and start from scratch? i guess what you know all of us are trying to understand is to what extent are you ready to throw out the rule book and start from scratch I'll put it bluntly, that's really, I think, what we're all trying to understand. i'll put it bluntly that's really i think what we're all trying to understand I don't know if you can comment on that. i don't know if you can comment on that

Speaker 4: No, I think it's too early for me to comment on it. I think I'm gonna stay the course and, you know, believe in the strategy that I have. No, I think it's too early for me to comment on it. no i think it's too early for me to comment on it I think I'm gonna stay the course and, you know, believe in the strategy that I have. i think i'm gonna stay the course and you know believe in the strategy that i have

Speaker 11: Got it. Thanks so much. Got it. got it Thanks so much. thanks so much

Speaker 10: The next question comes from the line of Martin Brenoe from Nordea. Please go ahead. The next question comes from the line of Martin Brenoe from Nordea. the next question comes from the line of martin brenoe from nordea Please go ahead. please go ahead

Speaker 8: Thank you very much for taking my questions, Anders and Gavin, and a warm welcome to you, Gavin. Veronika was asking most of my also pretty blunt questions here. Maybe just understanding, Gavin, on the wound care business. Given your background that you have as an outsider, you know, looking at the Coloplast in inside the wound industry, I would like to hear your early assessment of Coloplast wound care business. What shape do you see it, and what level of investments are needed to bring it to a competitive state? Maybe also your view on skin substitutes category. How do you view that market, and how do you see Kerecis playing a part of Coloplast going forward? Thank you very much for taking my questions, Anders and Gavin, and a warm welcome to you, Gavin. thank you very much for taking my questions anders and gavin and a warm welcome to you gavin Veronika was asking most of my also pretty blunt questions here. veronika was asking most of my also pretty blunt questions here Maybe just understanding, Gavin, on the wound care business. maybe just understanding gavin on the wound care business Given your background that you have as an outsider, you know, looking at the Coloplast in inside the wound industry, I would like to hear your early assessment of Coloplast wound care business. given your background that you have as an outsider you know looking at the coloplast in inside the wound industry i would like to hear your early assessment of coloplast wound care business What shape do you see it, and what level of investments are needed to bring it to a competitive state? what shape do you see it and what level of investments are needed to bring it to a competitive state Maybe also your view on skin substitutes category. maybe also your view on skin substitutes category How do you view that market, and how do you see Kerecis playing a part of Coloplast going forward? how do you view that market and how do you see kerecis playing a part of coloplast going forward

Speaker 4: Great. Thank you for the questions. Yeah, it actually, you know, early days, but it's also exciting to be back in wound care. It is an area I know well, and, you know, for those of you that don't know my background, I spent, you know, four and a half years at Mölnlycke and led this business, so I do know it well. It's a complex area, as everyone knows. That's something I think that we're all familiar with. It is the largest market that Coloplast is present in from a market opportunity. There are many competitors, and I'm excited to, you know, to be on the Coloplast side now to be able to drive our innovation. Great. great Thank you for the questions. thank you for the questions Yeah, it actually, you know, early days, but it's also exciting to be back in wound care. yeah it actually you know early days but it's also exciting to be back in wound care It is an area I know well, and, you know, for those of you that don't know my background, I spent, you know, four and a half years at Mölnlycke and led this business, so I do know it well. it is an area i know well and you know for those of you that don't know my background i spent you know four and a half years at mölnlycke and led this business so i do know it well It's a complex area, as everyone knows. it's a complex area as everyone knows That's something I think that we're all familiar with. that's something i think that we're all familiar with It is the largest market that Coloplast is present in from a market opportunity. it is the largest market that coloplast is present in from a market opportunity There are many competitors, and I'm excited to, you know, to be on the Coloplast side now to be able to drive our innovation. there are many competitors and i'm excited to you know to be on the coloplast side now to be able to drive our innovation I think what I see early days, and we're talking very early days, is I see some exciting developments that we can build on. Like, just take, you know, one example, the new Biatain Silicone Fit innovative technology. We won the award by Vizient in the U.S. That's an important recognition and an important milestone as we attempt to build a stronger position in the U.S. dressings business. I think longer term, you have to be strong in the U.S. market to win in advanced wound care. Then you asked a question a little bit around, you know, Kerecis and, you know, my perspective on, you know, skin substitutes. I think that this is a very interesting area, and what I like about Kerecis is that we are underpinned with strong clinical data. I think what I see early days, and we're talking very early days, is I see some exciting developments that we can build on. i think what i see early days and we're talking very early days is i see some exciting developments that we can build on Like, just take, you know, one example, the new Biatain Silicone Fit innovative technology. like just take you know one example the new biatain silicone fit innovative technology We won the award by Vizient in the U.S. we won the award by vizient in the u.s That's an important recognition and an important milestone as we attempt to build a stronger position in the U.S. dressings business. that's an important recognition and an important milestone as we attempt to build a stronger position in the u.s dressings business I think longer term, you have to be strong in the U.S. market to win in advanced wound care. i think longer term you have to be strong in the u.s market to win in advanced wound care Then you asked a question a little bit around, you know, Kerecis and, you know, my perspective on, you know, skin substitutes. then you asked a question a little bit around you know kerecis and you know my perspective on you know skin substitutes I think that this is a very interesting area, and what I like about Kerecis is that we are underpinned with strong clinical data. i think that this is a very interesting area and what i like about kerecis is that we are underpinned with strong clinical data I think that the market right now, it's a U.S. market, and some of the changes in the outpatient setting are a little bit unprecedented at time. I think it's gonna take time for this segment to arrive to a new normal. When you look forward, I think the intervention, you know, by the CMS and the segment of the market was needed to remove some unhealthy incentives that have kind of driven prices and spending to, you know, really, you know, remarkably unsustainable levels. However, the inpatient setting is governed by a completely different set of dynamics with strong emphasis on clinical evidence and efficacy and lower, more sustainable price levels. That's where Kerecis has a unique advantage with its proprietary fish skin technology. Kerecis is the only product based on intact fish skin. I think that the market right now, it's a U.S. market, and some of the changes in the outpatient setting are a little bit unprecedented at time. i think that the market right now it's a u.s market and some of the changes in the outpatient setting are a little bit unprecedented at time I think it's gonna take time for this segment to arrive to a new normal. i think it's gonna take time for this segment to arrive to a new normal When you look forward, I think the intervention, you know, by the CMS and the segment of the market was needed to remove some unhealthy incentives that have kind of driven prices and spending to, you know, really, you know, remarkably unsustainable levels. when you look forward i think the intervention you know by the cms and the segment of the market was needed to remove some unhealthy incentives that have kind of driven prices and spending to you know really you know remarkably unsustainable levels However, the inpatient setting is governed by a completely different set of dynamics with strong emphasis on clinical evidence and efficacy and lower, more sustainable price levels. however the inpatient setting is governed by a completely different set of dynamics with strong emphasis on clinical evidence and efficacy and lower more sustainable price levels That's where Kerecis has a unique advantage with its proprietary fish skin technology. that's where kerecis has a unique advantage with its proprietary fish skin technology Kerecis is the only product based on intact fish skin. kerecis is the only product based on intact fish skin It comes with benefits from a sourcing, production, and logistics perspective. More importantly, the technology is remarkable in healing severe, difficult-to-heal wounds. You know, these wounds are so severe that you're often at times looking at amputations as an alternative. The clinical efficacy of fish skin products is remarkable, and the clinical evidence really speaks for itself. As we look ahead, inpatient, you know, in the U.S. is becoming a larger share of our overall Biologics business. That's up from 70% today. This is where we feel really confident going forward, and winning the inpatient setting is going to be critical to winning the overall category. I'm still early into the role, I know as I've said a few times, and still learning about the business, but I'm already now encouraged by the clinical efficacy and evidence behind Kerecis. It comes with benefits from a sourcing, production, and logistics perspective. it comes with benefits from a sourcing production and logistics perspective More importantly, the technology is remarkable in healing severe, difficult-to-heal wounds. more importantly the technology is remarkable in healing severe difficult-to-heal wounds You know, these wounds are so severe that you're often at times looking at amputations as an alternative. you know these wounds are so severe that you're often at times looking at amputations as an alternative The clinical efficacy of fish skin products is remarkable, and the clinical evidence really speaks for itself. the clinical efficacy of fish skin products is remarkable and the clinical evidence really speaks for itself As we look ahead, inpatient, you know, in the U.S. is becoming a larger share of our overall Biologics business. as we look ahead inpatient you know in the u.s is becoming a larger share of our overall biologics business That's up from 70% today. that's up from 70% today This is where we feel really confident going forward, and winning the inpatient setting is going to be critical to winning the overall category. this is where we feel really confident going forward and winning the inpatient setting is going to be critical to winning the overall category I'm still early into the role, I know as I've said a few times, and still learning about the business, but I'm already now encouraged by the clinical efficacy and evidence behind Kerecis. i'm still early into the role i know as i've said a few times and still learning about the business but i'm already now encouraged by the clinical efficacy and evidence behind kerecis I also like this balance between, you know, wound care and Kerecis together. You know, that's what I would say at this point. I've got a lot of experience in both Europe and U.S., you know, this is what I intend to leverage as I start to get deeper into the business segments. I also like this balance between, you know, wound care and Kerecis together. i also like this balance between you know wound care and kerecis together You know, that's what I would say at this point. you know that's what i would say at this point I've got a lot of experience in both Europe and U.S., you know, this is what I intend to leverage as I start to get deeper into the business segments. i've got a lot of experience in both europe and u.s you know this is what i intend to leverage as i start to get deeper into the business segments

Speaker 8: Thank you. Thank you, Gavin. That's very clear. Thank you for the question. If I can just squeeze one follow-up question into Anders regarding the inflation on the costs and the plastic prices. Just wanted to be sure that I understand exactly how you forecast. I've spoken to distributors of plastic, and they're talking about massive price increases over the summer. It hasn't happened yet, but we're going to see it over the summer. Just want to be sure that when you talk about you haven't seen sort of the impact yet, whether that is the prices that you are getting now, or whether you have actually been in contact with distributors about the price increases that you expect in the coming months. Thank you. Thank you. thank you Thank you, Gavin. thank you gavin That's very clear. that's very clear Thank you for the question. thank you for the question If I can just squeeze one follow-up question into Anders regarding the inflation on the costs and the plastic prices. if i can just squeeze one follow-up question into anders regarding the inflation on the costs and the plastic prices Just wanted to be sure that I understand exactly how you forecast. just wanted to be sure that i understand exactly how you forecast I've spoken to distributors of plastic, and they're talking about massive price increases over the summer. i've spoken to distributors of plastic and they're talking about massive price increases over the summer It hasn't happened yet, but we're going to see it over the summer. it hasn't happened yet but we're going to see it over the summer Just want to be sure that when you talk about you haven't seen sort of the impact yet, whether that is the prices that you are getting now, or whether you have actually been in contact with distributors about the price increases that you expect in the coming months. just want to be sure that when you talk about you haven't seen sort of the impact yet whether that is the prices that you are getting now or whether you have actually been in contact with distributors about the price increases that you expect in the coming months Thank you. thank you

Speaker 2: Yeah, Martin, we are starting to see some of our raw material providers are contacting us. That's also what I'm basing my assumption for, in particular in Q4. What I said earlier, so far this year, we have not seen any impact yet, we are expecting some impact towards the end of this year, is in particular on some of the raw materials like injection molding, chemicals, films. That's how we see it currently. Yeah, Martin, we are starting to see some of our raw material providers are contacting us. yeah martin we are starting to see some of our raw material providers are contacting us That's also what I'm basing my assumption for, in particular in Q4. that's also what i'm basing my assumption for in particular in q4 What I said earlier, so far this year, we have not seen any impact yet, we are expecting some impact towards the end of this year, is in particular on some of the raw materials like injection molding, chemicals, films. what i said earlier so far this year we have not seen any impact yet we are expecting some impact towards the end of this year is in particular on some of the raw materials like injection molding chemicals films That's how we see it currently. that's how we see it currently

Speaker 8: Thank you. What's your opportunity to pass on the cost? Thank you. thank you What's your opportunity to pass on the cost? what's your opportunity to pass on the cost

Speaker 2: For this year, we have built that into the guidance we revised a few weeks ago. It's not going to be that material. We are going to manage that within the guidance we have given. For this year, we have built that into the guidance we revised a few weeks ago. for this year we have built that into the guidance we revised a few weeks ago It's not going to be that material. it's not going to be that material We are going to manage that within the guidance we have given. we are going to manage that within the guidance we have given

Speaker 8: Thank you very much for taking my questions. Thank you very much for taking my questions. thank you very much for taking my questions

Speaker 10: The next question comes from the line of Jan Koch from Deutsche Bank. Please go ahead. The next question comes from the line of Jan Koch from Deutsche Bank. the next question comes from the line of jan koch from deutsche bank Please go ahead. please go ahead

Speaker 6: Good morning. Thanks for taking my two questions. The first one is regarding Kerecis. To better understand the growth potential for the upcoming fiscal year, could you provide the projected share of the outpatient setting in your guidance by the end of this year? Secondly, it's more clarification on your European wound care business. You recently mentioned a reimbursement pressure in Germany due to announced price reforms. Are you referring to the broader healthcare reform aiming to reduce overall healthcare costs in Germany? What kind of, yeah, price reforms are you seeing in Germany? Thank you. Good morning. good morning Thanks for taking my two questions. thanks for taking my two questions The first one is regarding Kerecis. the first one is regarding kerecis To better understand the growth potential for the upcoming fiscal year, could you provide the projected share of the outpatient setting in your guidance by the end of this year? to better understand the growth potential for the upcoming fiscal year could you provide the projected share of the outpatient setting in your guidance by the end of this year Secondly, it's more clarification on your European wound care business. secondly it's more clarification on your european wound care business You recently mentioned a reimbursement pressure in Germany due to announced price reforms. you recently mentioned a reimbursement pressure in germany due to announced price reforms Are you referring to the broader healthcare reform aiming to reduce overall healthcare costs in Germany? are you referring to the broader healthcare reform aiming to reduce overall healthcare costs in germany What kind of, yeah, price reforms are you seeing in Germany? what kind of yeah price reforms are you seeing in germany Thank you. thank you

Speaker 2: Thanks for your questions. In terms of Kerecis, as we have been talking about at length, our inpatient business is around 70%-80% of the total Kerecis business. This year so far, we have been growing a solid double-digits, and we also are expecting that to continue. It's really in the outpatient setting where we have had a significant impact from the reimbursement changes in the U.S., and that is really impacting us. We expect that to continue in the coming quarters. We will be sitting around at a 0% growth for the year. You should see this year, 2025, 2026 as a reset. We have also talked quite a lot about that our focus is on inpatient. Thanks for your questions. thanks for your questions In terms of Kerecis, as we have been talking about at length, our inpatient business is around 70%-80% of the total Kerecis business. in terms of kerecis as we have been talking about at length our inpatient business is around 70%-80% of the total kerecis business This year so far, we have been growing a solid double- digits, and we also are expecting that to continue. this year so far we have been growing a solid double- digits and we also are expecting that to continue It's really in the outpatient setting where we have had a significant impact from the reimbursement changes in the U.S., and that is really impacting us. it's really in the outpatient setting where we have had a significant impact from the reimbursement changes in the u.s and that is really impacting us We expect that to continue in the coming quarters. we expect that to continue in the coming quarters We will be sitting around at a 0% growth for the year. we will be sitting around at a 0% growth for the year You should see this year, 2025, 2026 as a reset. you should see this year 2025 2026 as a reset We have also talked quite a lot about that our focus is on inpatient. we have also talked quite a lot about that our focus is on inpatient As we have mentioned a number of times, we have a strong product portfolio based on fish skin. We have good clinical documentation. We have actually just released some new clinical documentation. Therefore, we are expecting that our inpatient business will continue to outgrow the market and drive market share gains. In terms of your second question, about Germany, yes, that there is a general healthcare reform going on in Germany. We are, it's still in progress, so there are no, you can say, conclusions yet. We are just flagging that there might be an impact, in particular on our dressings business, probably more into the coming year with the knowledge we have. However, it's based on what is, the conclusions are going to be. As we have mentioned a number of times, we have a strong product portfolio based on fish skin. as we have mentioned a number of times we have a strong product portfolio based on fish skin We have good clinical documentation. we have good clinical documentation We have actually just released some new clinical documentation. we have actually just released some new clinical documentation Therefore, we are expecting that our inpatient business will continue to outgrow the market and drive market share gains. In terms of your second question, about Germany, yes, that there is a general healthcare reform going on in Germany. therefore we are expecting that our inpatient business will continue to outgrow the market and drive market share gains. in terms of your second question about germany yes that there is a general healthcare reform going on in germany We are, it's still in progress, so there are no, you can say, conclusions yet. we are it's still in progress so there are no you can say conclusions yet We are just flagging that there might be an impact, in particular on our dressings business, probably more into the coming year with the knowledge we have. we are just flagging that there might be an impact in particular on our dressings business probably more into the coming year with the knowledge we have However, it's based on what is, the conclusions are going to be. however it's based on what is the conclusions are going to be

Speaker 6: Okay, great. Thank you. Just a quick follow-up on my first question. Given that the outpatient channel is declining so significantly this year, how important is that channel for next fiscal year? Okay, great. okay great Thank you. thank you Just a quick follow-up on my first question. just a quick follow-up on my first question Given that the outpatient channel is declining so significantly this year, how important is that channel for next fiscal year? given that the outpatient channel is declining so significantly this year how important is that channel for next fiscal year

Speaker 2: Yeah. It's of course going to be less important, and our focus will be on inpatient. That's also how we set ourself up in our sales force. Yeah. yeah It's of course going to be less important, and our focus will be on inpatient. it's of course going to be less important and our focus will be on inpatient That's also how we set ourself up in our sales force. that's also how we set ourself up in our sales force

Speaker 6: Go ahead. Thank you. Go ahead. go ahead Thank you. thank you

Speaker 10: The next question comes from the line of Martin Parkhøi from SEB. Please go ahead. The next question comes from the line of Martin Parkhøi from SEB. the next question comes from the line of martin parkhøi from seb Please go ahead. please go ahead

Speaker 9: Yes, Martin Parkhøi from SEB. I only have one question left, and that's for Gavin, also welcome to Coloplast. You are of course joining a great company with actually growth rates which many companies would envy. I think that the one of the problems which have been in the last many years has been the ability to deliver on both short-term and long-term guidance. Maybe that has been a tad too high. Maybe you can share how have you been able to deliver on budgets in your former jobs, and what is your approach to making budgets and guidance? Are you more a conservative kind of guy or a bullish kind of guy? How should we see that? Yes, Martin Parkhøi from SEB. yes martin parkhøi from seb I only have one question left, and that's for Gavin, also welcome to Coloplast. i only have one question left and that's for gavin also welcome to coloplast You are of course joining a great company with actually growth rates which many companies would envy. you are of course joining a great company with actually growth rates which many companies would envy I think that the one of the problems which have been in the last many years has been the ability to deliver on both short-term and long-term guidance. i think that the one of the problems which have been in the last many years has been the ability to deliver on both short-term and long-term guidance Maybe that has been a tad too high. maybe that has been a tad too high Maybe you can share how have you been able to deliver on budgets in your former jobs, and what is your approach to making budgets and guidance? maybe you can share how have you been able to deliver on budgets in your former jobs and what is your approach to making budgets and guidance Are you more a conservative kind of guy or a bullish kind of guy? are you more a conservative kind of guy or a bullish kind of guy How should we see that? how should we see that

Speaker 4: First, Martin, thank you very much for the warm welcome and appreciate, you know, just once again, thrilled to be joining Coloplast and look forward to engaging with you in the future. I think, you know, I can't comment on guidance. Number one, it's too soon for me to kind of share a perspective here. I think that when you look at, you know, the previous organizations I worked in, it would be a little bit unfair as well. What I can share is I am deeply focused on a couple of things that I think will kinda give you an indication of the type of leader I am. I'm deeply focused on people, developing talent. I'm deeply focused on, you know, execution and driving growth. First, Martin, thank you very much for the warm welcome and appreciate, you know, just once again, thrilled to be joining Coloplast and look forward to engaging with you in the future. first martin thank you very much for the warm welcome and appreciate you know just once again thrilled to be joining coloplast and look forward to engaging with you in the future I think, you know, I can't comment on guidance. i think you know i can't comment on guidance Number one, it's too soon for me to kind of share a perspective here. number one it's too soon for me to kind of share a perspective here I think that when you look at, you know, the previous organizations I worked in, it would be a little bit unfair as well. i think that when you look at you know the previous organizations i worked in it would be a little bit unfair as well What I can share is I am deeply focused on a couple of things that I think will kinda give you an indication of the type of leader I am. what i can share is i am deeply focused on a couple of things that i think will kinda give you an indication of the type of leader i am I'm deeply focused on people, developing talent. i'm deeply focused on people developing talent I'm deeply focused on, you know, execution and driving growth. i'm deeply focused on you know execution and driving growth I believe in, you know, being a builder, building something for the future and I also believe that leaders should think like owners. When you get a group of people around this that are empowered and held accountable, and they have a common goal, I believe that you achieve, you know, really meaningful things together. I'm gonna reserve holding back on, you know, anything more specific at this time because it's just too new in my tenure. Thank you. I believe in, you know, being a builder, building something for the future and I also believe that leaders should think like owners. i believe in you know being a builder building something for the future and i also believe that leaders should think like owners When you get a group of people around this that are empowered and held accountable, and they have a common goal, I believe that you achieve, you know, really meaningful things together. when you get a group of people around this that are empowered and held accountable and they have a common goal i believe that you achieve you know really meaningful things together I'm gonna reserve holding back on, you know, anything more specific at this time because it's just too new in my tenure. i'm gonna reserve holding back on you know anything more specific at this time because it's just too new in my tenure Thank you. thank you

Speaker 2: All right. Thanks, Martin. That was the last questions, so we will conclude the conference call. Thanks a lot, Gavin, and again, a warm welcome to Coloplast. We are looking forward to see you on the street. Just thanks a lot. All right. all right Thanks, Martin. thanks martin That was the last questions, so we will conclude the conference call. that was the last questions so we will conclude the conference call Thanks a lot, Gavin, and again, a warm welcome to Coloplast. thanks a lot gavin and again a warm welcome to coloplast We are looking forward to see you on the street. we are looking forward to see you on the street Just thanks a lot. just thanks a lot

Speaker 4: Thank you. Thank you. thank you